<SEC-DOCUMENT>0001213900-25-119702.txt : 20251209
<SEC-HEADER>0001213900-25-119702.hdr.sgml : 20251209
<ACCEPTANCE-DATETIME>20251209164427
ACCESSION NUMBER:		0001213900-25-119702
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20251209
DATE AS OF CHANGE:		20251209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-287313
		FILM NUMBER:		251559673

	BUSINESS ADDRESS:	
		STREET 1:		10740 THORNMINT ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		10740 THORNMINT ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea0268590-424b5_modular.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: Red"><B>The information contained
in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement
relating to the securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement
and the accompanying prospectus are not an offer to sell nor do they seek an offer to buy these securities in any jurisdiction where
the offer or sale is not permitted.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Red"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="color: Red"><B>Subject to Completion,
Dated December 9, 2025</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>PRELIMINARY PROSPECTUS SUPPLEMENT</B></FONT></TD>
    <TD STYLE="width: 49%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Filed Pursuant to Rule 424(b)(5)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>(to Prospectus dated May 22, 2025)</B></FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt"><B>Registration No. 333-287313</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT=""><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Shares of Common Stock or </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants to Purchase Two Shares of Common Stock
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Shares of Common Stock Underlying the Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering shares of common stock of Modular
Medical, Inc. (the &ldquo;Company,&rdquo; &ldquo;Modular Medical,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us&rdquo;), par
value $0.001 per share, which we refer to as the &ldquo;common stock,&rdquo; and warrant (each, a &ldquo;warrant&rdquo;) to purchase share
of our common stock. Each two shares of common stock are being offered and sold together with an accompanying warrant at a combined offering
at a price of $ .</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not intend to apply for listing of the warrants
on any national securities exchange. The shares of our common stock and the accompanying warrants are immediately separable and will be
issued separately, but can only be purchased together in this offering. The warrants are exercisable immediately,
will expire five years from the date of issuance and have an exercise price of $ per share. This offering also includes the shares of
common stock issuable from time to time upon exercise of the warrants. The warrants will be issued in book-entry form pursuant to a warrant
agency agreement between us and Colonial Stock Transfer Company, Inc. as warrant agent (the &ldquo;Warrant Agent&rdquo;).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on the Nasdaq Capital
Market, or Nasdaq, under the symbol &ldquo;MODD.&rdquo; On December 8, 2025, the last reported sale price of our common stock was $0.4421
per share. The combined public offering price per two shares of common stock and accompanying warrant will be determined at the time of
pricing and may be at a discount to the current market price. The recent market price used throughout this prospectus supplement may not
be indicative of the final offering price. There is no established trading market for the warrants, and we do not expect a market to develop.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 8, 2024, the aggregate market
value worldwide of our outstanding voting and non-voting common equity held by non-affiliates, as calculated pursuant to the rules
of the Securities and Exchange Commission, was approximately $37,415,544, based on 55,844,096 shares of common stock outstanding
held by non-affiliates at a per common share price of $0.67 based on the closing sale price of our common shares on the Nasdaq
Capital Market on October 9, 2025. During the prior 12 calendar month period that ends on and includes the date hereof, we have sold
securities of $1,974,198 pursuant to General Instruction I.B.6 to Form S-3.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price <BR> Per Two<BR>
 Shares and<BR>
 Accompanying<BR>

                                                                                                 Warrant</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price Per Pre-Funded Unit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions <SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Proceeds to us (before expenses) <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The underwriter will receive compensation in addition to the underwriting discount. See &ldquo;Underwriting&rdquo; beginning on page S-15.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount of offering proceeds to us presented in this table does not give effect to any exercise of the: (i) over-allotment Option we have granted to the underwriter as described below and (ii) the underwriter&rsquo;s warrants being issued to the underwriters as described below.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the underwriter an option for
a period of 30 days from the date of this prospectus supplement to purchase up to an additional shares of common stock and up to an additional
warrants to cover overallotments at the public offering price, less underwriting discounts and commissions. The over-allotment Option
may be elected with respect to, at the Underwriter&rsquo;s sole discretion, Option Shares and Option Warrants together, solely Option
Shares, solely Option Warrants, or any combination thereof. If the underwriter exercises its option in full, the total underwriting discounts
and commissions payable by us will be $ , and the total proceeds to us, before expenses, will be $ .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. See &ldquo;<I>Risk Factors</I>,&rdquo; beginning on page S-7.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus
supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery of the securities offered hereby is expected
to be made on or about December [&nbsp;&nbsp;&nbsp;], 2025, subject to satisfaction of certain customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Book-Running Manager</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Newbridge Securities Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; width: 8%"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_001">ABOUT
    THIS PROSPECTUS SUPPLEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_002">PROSPECTUS
    SUPPLEMENT SUMMARY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_003">THE
    OFFERING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_004">RISK
    FACTORS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_005">SPECIAL
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_006">USE
    OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-11</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_007">DIVIDEND
    POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_008">DILUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-13</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_009">DESCRIPTION
    OF SECURITIES WE ARE OFFERING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_010">UNDERWRITING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-15</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_011">LEGAL
    MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_012">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_013">INCORPORATION
    OF CERTAIN INFORMATION BY REFERENCE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-18</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_014">WHERE
    YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-19</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_002"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_003"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_004"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_006"><FONT STYLE="font-size: 10pt">GENERAL DESCRIPTION OF SECURITIES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">9-14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_007"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_008"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_009"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_010"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_011"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s_001"></A><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
prospectus are part of a &ldquo;shelf&rdquo; registration statement on Form S-3 that we filed with the U.S. Securities and Exchange Commission
(the &ldquo;SEC&rdquo;), using a &ldquo;shelf&rdquo; registration process. This prospectus supplement describes the specific terms of
this offering. The accompanying prospectus, including the documents incorporated by reference therein, provides general information about
us and our securities, some of which, such as the section therein titled &ldquo;Underwriting,&rdquo; may not apply to this offering. Generally,
when we refer to this prospectus, we are referring to both this prospectus supplement and the accompanying prospectus, combined.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge you to carefully read this prospectus
supplement, the accompanying prospectus, the documents incorporated by reference herein and therein and the additional information under
the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo; before
buying any of the securities being offered under this prospectus supplement. These documents contain information you should consider when
making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information contained
or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not, and the underwriters have not,
authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should
not rely on it. This prospectus supplement may add, update or change information contained in the accompanying prospectus. To the extent
any information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on the information in
this prospectus supplement. The information in this prospectus supplement will be deemed to modify or supersede the information in the
accompanying prospectus and the documents incorporated by reference therein, except for those documents incorporated by reference therein
which we file with the SEC after the date of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should not assume that the information contained
or incorporated by reference in this prospectus supplement and the accompanying prospectus is accurate on any date subsequent to the date
set forth on the front cover of this prospectus supplement and the accompanying prospectus or on any date subsequent to the date of the
document incorporated by reference herein or therein, as applicable. Our business, financial condition, results of operations and prospects
may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering to sell, and seeking offers to
buy, the securities described in this prospectus supplement only in jurisdictions where offers and sales are permitted. The distribution
of this prospectus supplement and the offering of the securities in certain jurisdictions may be restricted by law. Persons outside the
United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating
to, the offering of the securities and the distribution of this prospectus supplement outside the United States. This prospectus supplement
does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered
by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We further note that the representations, warranties
and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference into this prospectus
supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases,
for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or
covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such
representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement and the accompanying
prospectus contain and incorporate by reference certain market data and industry statistics and forecasts that are based on management&rsquo;s
own estimates, independent industry publications, government publications, reports by market research firms and other publicly available
information. Although we believe these sources are reliable, estimates as they relate to projections involve numerous assumptions, are
subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under &ldquo;<I>Risk
Factors</I>&rdquo; in this prospectus supplement and the accompanying prospectus and under similar headings in the documents incorporated
by reference herein and therein. Accordingly, investors should not place undue reliance on this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used in this prospectus, except as otherwise
indicated herein or as the context otherwise requires, references in this prospectus to &ldquo;Modular Medical,&rdquo; the &ldquo;Company,&rdquo;
&ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to Modular Medical, Inc. and its wholly-owned subsidiary, Quasuras, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><A NAME="s_002"></A>PROSPECTUS SUPPLEMENT
SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>This summary highlights
selected information contained elsewhere in this prospectus supplement and does not contain all the information that you should consider
before making your investment decision. Before investing in our securities, you should carefully read this entire prospectus supplement,
including the information set forth under the &ldquo;Risk Factors&rdquo;, under the headings &ldquo;Item 1A. Risk Factors&rdquo; in our
Annual Report on Form 10-K for the year ended March 31, 2025, our Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025
and September 30, 2025, respectively, and in our other filings with the SEC. Except as otherwise indicated herein or as the context otherwise
requires, references in this prospectus supplement to &ldquo;Modular Medical,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo;
and &ldquo;our&rdquo; refer to Modular Medical, Inc. and its wholly-owned subsidiary, Quasuras, Inc.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are a pre-revenue,
medical device company focused on the design, development, and commercialization of innovative insulin pumps using modernized technology
to increase pump adoption in the diabetes marketplace. Through the creation of an innovative two-part patch pump, we seek to fundamentally
alter the trade-offs between cost and complexity and access to the higher standards of care that presently require considerable motivation
from the patient to use the available insulin pumps. By simplifying and streamlining the user experience from the initial introduction
of the patient to our product, prescription assistance, establishing insurance reimbursement, streamlined training and day-to-day use
with strong clinical support, we seek to expand the wearable insulin delivery device market beyond the highly motivated &ldquo;super users&rdquo;
to expand the category into the mass market. Our product seeks to serve both the type 1 and the rapidly growing, especially in terms of
device adoption, type 2 diabetes markets for those individuals requiring multiple daily doses of insulin. In January 2024, we submitted
a 510(k) premarket notification to the United States Food and Drug Administration, or the FDA, for our initial insulin pump product, the
MODD1, and, in September 2024, we received FDA clearance to market and sell our MODD1 pump in the United States. In August 2025, we announced
the first human use of our MODD1 pump delivering insulin to a human patient. In addition, in August 2025, we announced our next-generation
patch pump, branded as Pivot. We submitted a 510(k) premarket notification to the FDA for our Pivot product on November 13, 2025, when
the United States government shutdown ended. We intend to initiate our commercial launch with our Pivot product, rather than the MODD1
product, when the required regulatory approval from the FDA is received, which is expected in the first quarter of 2026. We are actively
working to i) obtain regulatory clearance and prepare to commence commercialization of our Pivot product, ii) obtain regulatory clearance
to market and sell our Pivot product in foreign jurisdictions, iii) improve the manufacturability and usability of our Pivot product and
iv) develop new pump products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Differentiation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We believe that there
are a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of people who require
insulin on a daily basis from choosing an insulin pump to treat their diabetes. We believe that, by tailoring our insulin pump to address
such factors, we can expand the scope and adoption rate of insulin pump usage by the less capable, less motivated sector of the market.
We believe that to achieve broader market acceptance, an insulin pump must be easier to learn to use, be less time-consuming to operate,
more intuitive to both patients and physicians, and meet the standards for coverage by insurance providers so that co-payments required
from patients are affordable and the hurdles to insurance coverage are significantly reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Among the more prominent issues are</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Complexity: Many existing pumps are highly complex and require
significant technical expertise to use effectively. We believe such pumps were designed for &ldquo;super users,&rdquo; who have high
levels of motivation and technical competence. The complexity of pumps can be daunting to less technically inclined, less motivated users.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Cumbersome: We believe that a majority of existing pumps
are bulky and difficult to manage, requiring a means of carrying the pump around and up to 48 inches of tubing to the injection site
to connect the catheter to a pump. The tubing and the cartridge, which holds the insulin, must be replaced every few days. This requires
users to carry spare parts and other equipment adding to the difficulty of using the pump. In comparison, our product only requires a
cartridge change every few days.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Cost: Costs associated with insulin pump therapy can be high
and prohibitive, especially for those on fixed or limited incomes. These costs vary by pump and insurance coverage, but multi-thousand-dollar
upfront payments, often with substantial co-payments in addition to possible additional co-payments on consumables, can easily place
current pumps out of reach for many patients. The leading patch pump on the market today also discards all the electronics required for
pumping and communication every three days, creating a higher cost architecture and significant waste. We believe the reusability of
our product will provide us with a significant cost advantage in the marketplace with our reusable pumping system.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Outdated style: Consumer electronics devices have evolved
in both form and function. Diabetes pumps have not experienced similar progress. We believe that consumers will be more receptive of
products designed with the user experience in mind and that many have low tolerance for complex, difficult procedures for use and maintenance
of products.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Pump mechanism limitations: Traditional pumps generally utilize
a syringe and plunger mechanism to deliver insulin. We believe this design limits the ability to reduce the size of the pump, and also
potentially exposes the user to the unintended delivery of the full volume of insulin within the pump, which can cause hypoglycemia or
death. We believe that the fear of adverse health events due to technical malfunctions related to traditional pump mechanism limitations
deters the adoption of insulin pump therapy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our team has substantial
knowledge of the diabetes industry and experience in developing, obtaining marketing authorization for, and bringing insulin pumps to
market. Based on this experience, we believe that our innovative insulin pump, using a new and proprietary method of pumping insulin,
can address most or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady flow) and bolus
(mealtime dosing) insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid pumps,
potentially offering an exciting array of new therapies to patients with diabetes and other conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our goal is to become
the leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the super
users, but &ldquo;diabetes care for the rest of us.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">While our initial target
market is people with Type 1 diabetes, we believe there is a substantial opportunity to penetrate the type 2 marketplace, first through
our initial MODD1 pump, and then with the future introduction of Pivot, which would be the only 3 milliliter, tubeless removable patch
pump on the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our insulin delivery
systems are high-precision pumps that we believe represent the best choice for new pump patients because they are affordable, easy to
learn and use, and has a revolutionary design and internal technology that enable precision with low-cost manufacture and high reproducibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Key features include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Three parts - one reusable, two disposable (the cartridge
and the set) - snap together to form the working system;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">One button interface, easy to learn and use;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Phone software for those who want to access more information
on the product;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">90-day reusable, 3-day disposable;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Removable system;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">No external controller required, no charging, no battery
replacement; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Slim profile, lighter weight.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">A proprietary survey
of American healthcare payors representing 50 million covered lives (approximately one-third of total U.S. covered lives) performed for
us by industry leading survey firm ISA in 2019 has demonstrated that payors are willing to grant equivalent or preferential coverage for
a product with this feature set at launch in exchange for discounts of approximately 20%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Diabetes Classifications
and Therapies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Diabetes is typically
classified as either type 1 or type 2:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Type 1 diabetes, or T1D, is an auto-immune condition characterized
by the body&rsquo;s nearly complete inability to produce insulin. It is frequently diagnosed during childhood or adolescence, although
it can sometimes have onset in adulthood. Individuals with T1D require daily insulin therapy to survive.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Type 2 diabetes, or T2D, represents over 90% of all individuals
diagnosed with diabetes and is characterized by the body&rsquo;s inability to either properly utilize insulin or produce sufficient insulin.
Initially, many people with T2D attempt to manage their condition with improvements in diet and exercise and/or the use of oral medications
and/or injection of glucagon-like peptide-1 (GLP-1) drugs. However, as their diabetes advances, patients often progress to requiring
insulin therapies such as once-daily long-acting insulin and ultimately to intensified mealtime rapid-acting insulin therapy. This represents
an important portion of the diabetes market with an estimated 1.6 million individuals with T2D intensively treated with insulin currently
in the United States.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Glucose, the primary
source of energy for cells, must be maintained at certain levels in the blood in order to permit optimal cell function and health. The
brain works on pure glucose, and, when sufficient glucose is available, the brain allows insulin to be released that allows the cells
to absorb glucose. In people with diabetes, blood glucose levels are not well controlled by the brain due to the shortage of insulin.
Frequently, blood glucose levels become very high, a condition known as hyperglycemia, or very low, a condition called hypoglycemia. Hyperglycemia
can lead to serious long-term complications, including blindness, kidney disease, nervous system disorders, occlusive vascular diseases,
lower-limb amputation, stroke, cardiovascular disease, and death. Hypoglycemia can lead to confusion or loss of consciousness, often requiring
a visit to the emergency room or, in certain cases, result in seizures, coma, and/or death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">All people with T1D,
which is our primary market, require daily insulin. According to the Seagrove 2023 Diabetes Blue Book, there are approximately 3.6 million
potential users for insulin pumps, split evenly between type 1 and type 2. In this Report, we refer to people with T1D and people with
T2D who require mealtime insulin as &ldquo;insulin-requiring people with diabetes.&rdquo;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Currently, there are
two primary therapies available for insulin-requiring people with diabetes: multiple daily insulin injections directly into the body through
syringes or insulin pens (a type of syringe), referred to as Multiple Daily Injection, or MDI therapy, or the use of an insulin pump to
deliver mealtime insulin boluses to help with glucose absorption after carbohydrate consumption and a continuous subcutaneous insulin
infusion, or CSII therapy, into the body. Generally, CSII therapy is considered to provide a number of advantages over MDI therapy, primarily
an improvement in glycemic control, as measured by certain diabetes management tests such as hemoglobin A1c (HbA1c) measure and more recently
Time in Range (TIR) where a continuous glucose measuring device is used to calculate this test. Among other clinical benefits, a study
conducted by Tandem Diabetes Care, Inc., or Tandem, in 2021, demonstrated that insulin pump use can decrease glucose variability, reduce
the number of hypoglycemia events, and reduce the fear of hypoglycemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Notwithstanding these
advantages, we believe the difficulty in use resulting from the complexity and cumbersome design of available insulin pumps, as well as
high and often prohibitive costs for both the patient and insurance provider, has resulted not only in dissatisfaction among many existing
pump users. We believe the cost and complexity to the user has severely limited the adoption rate of insulin pumps by a large segment
of the diabetes population using MDI therapy, whom we refer to in this Report as &ldquo;Almost Pumpers.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We define Almost Pumpers
as insulin-requiring people with diabetes who are aware of pumps and their potential benefits but because of past experiences, pump shortcomings,
cost, complexity, and time and learning required to adopt and utilize currently available insulin pumps, continue to receive their daily
insulin through MDI therapy. We undertook one-on-one interviews with over 200 of these individuals to understand their past experiences
on or considering pumps, existing pump shortcomings, the cost and insurance challenges, complexity to learn and time and complexity to
operate that drives them to remain on MDI. With this detailed understanding, we brought a series of prototype models to them to react
to, so we could refine the design and include features that would motivate them to be able to use this technology to better care for their
diabetes. Our pump products have been well received by these individuals and our clinical advisors, as applicable for this sector of the
marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our research, along with
marketplace data provided by Seagrove in 2023, estimates that 33% of Americans with T1D have an insulin pump and 28% of Americans with
T1D (44% of those who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the American Diabetes
Association guidelines of glucose control if their objections to the currently available suite of products can be overcome. They do not
want to closely manage their glucose levels and incur the associated time and effort involved; however, they understand, or are advised
by their clinical care team, that they need to do more to achieve a reasonable level of glucose. They are the Almost Pumpers. We have
developed what we believe to be the most technologically advanced delivery system overcome the objections and provide motivation for this
market. We believe that there are four addressable hurdles to adoption:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Usability: the device needs to be easy to learn and to operate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Affordability: we will focus on overcoming copay and insurance
hurdles rather than leaving the &ldquo;insurance journey&rdquo; to the clinician and patient;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Accessibility and Education: we will seek to engage patients
to sample this new technology by supplying clinicians with free samples and simple training to allow people to see first-hand the typical
barriers to adoption that have been overcome; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Service and Support: where we will answer their questions
and concerns during this diabetes experience.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: white">We believe this conversion process, engaging
people to try and thereby receive the benefits of our technology will substantially increase adoption of insulin pumps among both those
with T1D and Type 2 diabetes who remain reliant upon multiple daily injections. Diabetes is a disease that appears throughout the world.
Therefore, we cannot segment the market by socioeconomics, education or level of care. We intend to create an insulin pump that appeals
to all Almost Pumpers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Our Insulin Pump</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Instead of building complex,
bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology and the user in mind. Using
proprietary methods of insulin measurement, we were able to eschew complex mechanisms and instead built our pump products, using only
parts from high volume consumer electronics manufacturing lines, breaking the cost vs functionality curve that has existed in the insulin
pump space and representing the first truly modern insulin pump design. We consider this to be a new kind of product for a new kind of
patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have moved our production
line for our Pivot product to our manufacturing partner, Phillips Medisize, a Molex company, a large tier-one medical device manufacturer,
which will manage and operate our production to produce products for human use. We believe that Phillips Medisize will be able to rapidly
scale our production to higher volumes at lower cost. We continue to devote substantial time and resources, including exhibiting at major
diabetes conferences, to better understand the needs and preferences of Almost Pumpers and the specific patient/provider/payor requirements
to motivate change from MDI therapy. By making the bolus delivery at meals simple, we believe we will drive improved health outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Our Pivot product has several distinguishing
features:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><IMG SRC="image_002.jpg" ALT=""><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in">1.&nbsp;The
pump has a simple button to press to deliver insulin as the patient requires it. The electronic pump uses a simple motor for rotating
a cam to motivate the insulin into the patient along with low power Bluetooth and near-field communication (NFC) chips to optionally allow
the patient to communicate with a smart phone, tablet, or other mobile computing device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in">2.&nbsp;The
pump snaps together with a three-day disposable cartridge, which the patient fills with insulin for delivery. It includes a simple coin
cell, which allows it to run through the 80-hour life of the cartridge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.25in">3.&nbsp;The
infusion set is built into the adhesive pad that the pump attaches to and the needle can be safely removed and discarded by the user after
application. Despite this true patch form factor, the pump is removable by the user during the three days of wear.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The system will deliver
a small continuous rate called a basal that will provide approximately 50% of the total daily dose required, and the user will use the
on-pump button to administer boluses, typically before and after meals. The objective is to make the product simple to acquire and take
home, simple to learn and most importantly, simple to use and live with, to expand the pump market, drive adoption and, ultimately, improve
clinical outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Commercialization Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We plan to commercialize
our Pivot product line using a highly differentiated go-to-market strategy. Generally, current pumps are marketed by a large, direct
sales force to end users directly, and the manufacturer provides all training and support, as the current training reimbursement offered
by insurance providers is inadequate to motivate clinicians to provide such training to patients. We intend to employ a different strategy
and utilize i) distributors to target the daily insulin users who are still managed by a primary care physician and ii) a small direct
sales force to directly engage with diabetes educator practices. Specifically, our direct sales force will engage with larger diabetes
educator practices, which currently prescribe a high volume of pumps and deliver a consultative message focused on those users that indicate
a desire to use a pump but have rejected all of the currently available options. We engaged Seagrove to conduct a survey of physicians
and diabetes educators, and the resulting data suggested that approximately 25% of multiple daily injectors could be receptive to our
offering. We believe that the modest 30-minute training requirement for our product, combined with the more limited feature set for our
Pivot product, will incentivize nurse practitioners to identify and train new users who have not been offered pumps before. This would
also allow us to offer virtual or second level training support and not require us to be the primary training provider.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We plan to launch our
Pivot product during the quarter ending March 31, 2026, after we receive the required FDA approval. We believe the new integrated insulin-delivery
set will offer improved user experience, while reducing our production costs. This new version of our product, the Pivot, is the version
that we plan to launch nationally in the United States after we receive FDA clearance, which we expect could occur sometime in the first
quarter of 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have also begun the
process of obtaining&nbsp;<I>Conformite Europeenne</I>, or CE, mark clearance for our Pivot design, which would allow us to market and
sell in European markets. We expect to obtain CE mark clearance in 2026. Our initial strategy to address European markets is to partner
with distributors to bring the Pivot to market in those countries that accept the CE mark and have acceptable reimbursement. We believe
that the combination of our patch pump form factor, lower cost at scale and lower training burden is well suited for European markets
where there are very few physicians or nurses available to provide training. This would allow the Pivot to gain rapid adoption in areas
where pump penetration is currently much lower than in the United States. We will target other select international markets using the
same approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We believe the combination
of these differentiated approaches will enable us to take reasonable initial market share, while not incurring the significant overhead
cost of existing commercialization strategies employed by the incumbents, where competition for users is intense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
10740 Thornmint Road, San Diego, CA 92127 and our telephone number is (858) 800-3500. We maintain a website at www.modular-medical.com.
Information contained on, or accessible through, our website does not constitute a part of this prospectus supplement or our other filings
with the SEC, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus
supplement or in deciding whether to purchase our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_003"></A>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%"><FONT STYLE="font-size: 10pt">Securities offered by us: </FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 75%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    shares of common stock. Each two&nbsp;shares of common stock is being offered and sold together with one warrant to purchase share
    of our common stock. The shares of our common stock and the
    warrants will be issued separately, but will be purchased together in this offering.</P>
    </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">Description of the warrants:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">

    &nbsp;Warrants to purchase shares of common stock may only be exercisable
for a whole number of shares of common stock and, because the warrants will only be sold along with shares of common stock, no fractional
shares or warrants to purchase fractional shares will be issued in this offering. The exercise price of the warrants is $ per share. Each
warrant will be exercisable immediately upon issuance and will expire five years after the initial issuance date. This prospectus supplement
also relates to the offering of the shares of common stock issuable upon exercise of the warrants. For more information regarding the
warrants, you should carefully read the section titled &ldquo;<I>Description of Securities We are Offering &ndash; Warrants</I>&rdquo;
in this prospectus supplement.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Common stock outstanding prior to this offering<SUP>(1)</SUP>: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">63,677,389 shares of common stock outstanding as of December 8, 2025. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Common stock to be outstanding after this offering<SUP>(1)</SUP>: </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp; shares of common stock or &nbsp;&nbsp;&nbsp; shares of common stock if the over-allotment option granted to the underwriter is exercised in full, assuming no exercises of the warrants, </FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Use of proceeds: </FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the net proceeds from this
offering will be approximately $&nbsp;&nbsp;&nbsp;, after deducting underwriting discounts and commissions and the estimated offering
expenses payable by us, excluding any proceeds received upon exercise of the warrants and the underwriter warrants.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to use the net proceeds of this offering for general corporate
purposes, including capital expenditures and working capital. See &ldquo;Use of Proceeds.&rdquo;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Over-allotment option</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We have granted a 30-day option to the underwriter, exercisable one or more times in whole or in part, to purchase up to an additional &nbsp;&nbsp;&nbsp; shares of common stock at the effective public offering price per share of $&nbsp;&nbsp;&nbsp; and additional warrants to purchase up to &nbsp;&nbsp;&nbsp; additional shares of common stock at a price of $&nbsp;&nbsp;&nbsp; per warrant, in each case less underwriting discounts and commissions, to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Risk factors:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Investing in our securities involves substantial risk. You should read
    the &ldquo;<I>Risk Factors</I>&rdquo; section beginning on page S-7 and in the documents incorporated by reference in this
    prospectus supplement and accompanying prospectus for a discussion of factors to consider before deciding to invest in our
    securities.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="border: Black 1.5pt solid; padding-right: 5.4pt; padding-left: 5.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 22%"><FONT STYLE="font-size: 10pt">Lock-ups</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 75%"><FONT STYLE="font-size: 10pt">We and our directors and officers have agreed with the
    underwriters not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or
    securities convertible into common stock for a period of three (3) months and sixty (60) days, respectively, after the date of this
    prospectus supplement. See &ldquo;<I>Underwriting</I>&rdquo; section.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in"><FONT STYLE="font-size: 10pt">Nasdaq Capital Market Symbol</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">MODD</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of our common stock outstanding
before and after this offering is based on 63,677,389 shares of our common stock outstanding as of December [&nbsp;&nbsp;&nbsp;], 2025 and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">3,001,464 shares of common stock reserved for issuance under
our Amended and Restated 2017 Equity Incentive Plan;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">7,300,747 shares of common stock issuable upon the exercise
of options outstanding, with a weighted average exercise price of $2.39 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">62,501 shares of common stock issuable upon vesting of restricted
stock units;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">767,796 shares of common stock issuable upon exercise of
warrants outstanding at $6.00 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">5,449,478 shares of common stock issuable upon exercise of
warrants outstanding at $6.60 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">484,006 shares of common stock issuable upon exercise of
warrants outstanding at $1.325 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,671,733 shares of common stock issuable upon exercise of
warrants outstanding at $1.22 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">381,540 shares of common stock issuable upon exercise of
warrants outstanding at $1.875 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,905,042 shares of common stock issuable upon exercise of
warrants outstanding at $1.12 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">874,672 shares of common stock issuable upon exercise of
warrants outstanding at $1.40 per share;  and</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">3,243,116 shares of common stock issuable upon exercise of warrants
outstanding at $0.84 per share.</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise indicated, all information
in this prospectus supplement assumes (i) no exercise by the underwriter of its over-allotment option and (ii) no issuances of common
stock under the outstanding equity awards and warrants described above, including the warrants offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s_004"></A><B>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>An investment in our securities involves a
high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks described below, together
with other information in this prospectus supplement, the accompanying prospectus and the information and documents incorporated by reference.
You should also consider the risks, uncertainties and assumptions discussed under the heading &ldquo;Risk Factors&rdquo; included in our
most recent Annual Report on Form 10-K and the subsequent reports that we file with the SEC which are on file with the SEC and are incorporated
herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the
future. If any of these risks actually occur, our business, financial condition, results of operations or cash flow could be adversely
effected. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. The
risks and uncertainties described below are not the only ones facing us. Additional risks and uncertainties not presently known to us,
or that we currently see as immaterial, may also harm our business. Please also read carefully the section below entitled &ldquo;Special
Note Regarding Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Business and Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We might not be able to continue as a going
concern.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our condensed consolidated financial
statements as of September 30, 2025 have been prepared under the assumption that we will continue as a going concern twelve months
from the date of this prospectus supplement. At September 30, 2025, we had cash and cash equivalents of $5.3 million and an
accumulated deficit of approximately $99.2 million. In September 2025, we effected a warrant inducement offering for net proceeds of
approximately $3.9 million, and, during the six months ended September 30, 2025, we generated net proceeds of approximately $0.7
million from sales under our at-the-market sales program. In March 2025, we completed a private placement of common stock and
warrants for net proceeds to us of approximately $11.4 million. Even with these proceeds, we do not believe that our cash and cash
equivalents will be sufficient to fund our operations for the period of 12 months from the date of this prospectus supplement, and
we will need to raise additional capital. As a result of our expected operating losses and cash burn for the foreseeable future and
recurring losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements, there
will be uncertainty regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises
substantial doubt as to our ability to continue as a going concern. If we cannot continue as a viable entity, our stockholders would
likely lose most or all of their investment in us. If we are unable to generate sustainable operating profit and sufficient cash
flows, then our future success will depend on our ability to raise capital. We intend to seek additional financing and evaluate
financing alternatives in order to meet our cash requirements for the foreseeable future. We cannot be certain that raising
additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will
be available to us or, if available, will be on terms acceptable to us. If we issue additional securities to raise funds, these
securities may have rights, preferences, or privileges senior to those of our common stock, and our current stockholders may
experience dilution. If we are unable to obtain funds when needed or on acceptable terms, we may be required to curtail our current
product development programs, cut operating costs, forego future development and other opportunities or even terminate our
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to satisfy the continued
listing requirements of the Nasdaq, our common stock could be delisted and the price and liquidity of our common stock may be adversely
affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock may lose value and could be delisted
from Nasdaq due to several factors or a combination of such factors. While our common stock is currently listed on Nasdaq, we can give
no assurance that we will be able to maintain compliance with the continued listing requirements of Nasdaq, including, but not limited
to, the corporate governance requirements, the minimum closing bid price requirement or the minimum equity requirement. If we fail to
maintain compliance with any such continued listing requirement, there can also be no assurance that we will be able to regain compliance
with any such continued listing requirement in the future or that our common stock will not be delisted in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2025, we received a letter from the
Listing Qualifications Staff of Nasdaq indicating that, based upon the closing bid price of our common stock for the 30 consecutive business
days ending on June 27, 2025, we no longer meet the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq
Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided a period of 180 calendar days, or
until December 29, 2025, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing
bid price of our common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period.
In the event we do not regain compliance within this 180-day period, we may be eligible to seek an additional compliance period of 180
calendar days provided it meets the continued listing requirement for market value of publicly held shares and all other initial listing
standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and further provides written notice to Nasdaq
of its intent to cure the deficiency during this second compliance period by effecting a reverse stock split, if necessary. However, if
it appears to the Nasdaq staff that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq will provide
notice to us that the common stock will be subject to delisting. The letter does not result in the immediate delisting of the common stock
from the Nasdaq. We are monitoring the closing bid price of the common stock and considering available options in the event the closing
bid price of our common stock remains below $1 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we were to be delisted, we would expect our
common stock to be traded in the over-the-counter market which could adversely affect the liquidity of our common stock. Additionally,
we could face significant material adverse consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a limited availability of market quotations for our common
stock;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">a decreased ability to issue additional securities or obtain
additional financing in the future;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">reduced liquidity for our stockholders;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">potential loss of confidence by customers, collaboration
partners and employees; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">loss of institutional investor interest.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of a delisting, we can provide no
assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again,
stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum
bid price requirement, or prevent future non-compliance with Nasdaq&rsquo;s listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to This Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>After this offering, we will need to raise
additional capital in the future to execute our business plan.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect the net proceeds to us from this offering
will approximate $[&nbsp;&nbsp;&nbsp;], which assumes that the over-allotment option is not exercised. Upon closing of this offering, we expect to have
cash and cash equivalents of approximately $[&nbsp;&nbsp;&nbsp;]. After the closing of this offering, we believe we will have adequate funds to operate
our business for at least the next [&nbsp;&nbsp;&nbsp;] months. We will require additional funding to commercialize our pump product and bring it to market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that additional capital,
whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to us or,
if available, will be on terms acceptable to us. If we issue additional securities to raise funds, these securities may have rights, preferences,
or privileges senior to those of our common stock, and our current stockholders may experience dilution. If we are unable to obtain funds
when needed or on acceptable terms, we may be required to curtail our current product development programs, cut operating costs, forego
future development and other opportunities or even terminate our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>As we have broad discretion in how we use
the proceeds from this offering, we may use the proceeds in ways with which you disagree.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not allocated the net proceeds from this
offering for any specific purpose, except as generally set forth under &ldquo;<I>Use of Proceeds</I>.&rdquo; As set forth therein, our
management will have significant flexibility in applying the net proceeds of this offering. You will be relying on the judgment of our
management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to
assess whether the proceeds are being used in ways you would agree with or ways which are likely to increase the value of your investment.
Because of the number and variability of factors that will determine our use of our net proceeds from this offering, their ultimate use
may vary substantially from their currently intended use. It is possible that the net proceeds will be invested in a way that does not
yield a favorable, or any, return for our company or your investment. The failure of our management to use such funds effectively could
have a material adverse effect on our business, financial condition, operating results and cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B><I>Holders of our warrants
will have no rights as common stockholders until they acquire our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants being offered hereby do not confer
any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent
the right to acquire shares of our common stock at a fixed price for a limited period of time. Specifically, commencing on the date of
issuance, holders of the warrants may exercise their right to acquire the common stock and pay the exercise price per share, prior to
five years from the date of issuance, after which date any unexercised warrants will expire and have no further value. Until holders of
the warrants acquire common stock upon exercise of the warrants, the holders will have no rights with respect to the common stock issuable
upon exercise of the warrants. Upon exercise of the warrants, the holder will be entitled to exercise the rights of a stockholder as to
the security exercised only as to matters for which the record date occurs after the exercise. There can be no assurance that the market
price of the common stock will ever equal or exceed the exercise price of the warrants, and consequently, whether it will ever be profitable
for holders of the warrants to exercise the warrants.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Provisions of the warrants offered by this
prospectus supplement could discourage an acquisition of us by a third party</I></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the discussion of the provisions
of our governing organizational documents, certain provisions of the warrants offered by this prospectus supplement could make it more
difficult or expensive for a third party to acquire us. The warrants prohibit us from engaging in certain transactions constituting &ldquo;fundamental
transactions&rdquo; unless, among other things, the surviving entity assumes our obligations under the warrants. These and other provisions
of the warrants offered by this prospectus supplement could prevent or deter a third party from acquiring us even where the acquisition
could be beneficial to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The warrants offered by this prospectus
supplement are speculative in nature and may not have any value</I></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants offered by this prospectus supplement
will be exercisable for five years from the date of issuance. There can be no assurance that the market price of our common stock will
ever exceed the exercise price of the warrants. In the event that our common stock price does not exceed the exercise price of the warrants
during the term of the warrants, the warrants may not have any value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no public market for the warrants
being offered in this offering</I></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no public trading market for the warrants
offered by this prospectus supplement, and we do not expect a market to develop. In addition, we do not intend to apply to list the warrants
on a national securities exchange. Without an active market, the liquidity of the warrants will be limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>You will experience
immediate and substantial dilution in the net tangible book value per share of the common stock you purchase.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2025, our net tangible book
value was approximately $8,769,000, or approximately $0.143 per share of common stock. As the effective price per share of our common
stock being offered in this offering is substantially higher than the net tangible book value per share of our common stock, you will
suffer substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. Based on the
combined public offering price of $ per two shares of common stock and accompanying warrant being sold in this offering, and our net tangible
book value per share as of September 30, 2025, if you purchase shares of common stock in this offering, you will suffer immediate and
substantial dilution of $ per share with respect to the net tangible book value of the common stock. See the section titled &ldquo;<I>Dilution</I>&rdquo;
below for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>You will likely
experience future dilution as a result of future equity offerings and other issuances of our common stock or other securities. In addition,
this offering and future equity offerings and other issuances of our common stock or other securities may adversely affect the price of
our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In order to raise additional
capital, in the future, we expect to offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock (such as warrants, convertible debt or preferred stock) at prices that may not be the same as the price per share
in this offering. We may not be able to sell shares of common stock or other securities in any other offering at a price per share that
is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares of common stock or
other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares
of our common stock or securities convertible into common stock in future transactions may be higher or lower than the price per share
in this offering. In addition, the sale of shares of common stock in this offering and any future sales of a substantial number of shares
of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common
stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of
common stock for sale will have on the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_005"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement includes forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, which we refer to as the &ldquo;Securities Act,&rdquo;
and Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the &ldquo;Exchange Act,&rdquo; that relate to
future events or to our future operations or financial performance. Any forward-looking statement involves known and unknown risks, uncertainties
and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future
results, levels of activity, performance or achievements expressed or implied by such forward-looking statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Words such as, but not limited to, &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;forecast,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo;
&ldquo;plan,&rdquo; &ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;targets,&rdquo; &ldquo;likely,&rdquo;
&ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;continue,&rdquo; &ldquo;scheduled&rdquo; and
similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. Although we believe that we have a reasonable basis for each
forward-looking statement contained in this prospectus supplement, we caution you that these statements are based on our estimates or
projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our
actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by any
forward-looking statement. Actual results, level of activity, performance, experience or achievements may differ materially from those
expressed or implied by any forward-looking statement as a result of various important factors, including risks and uncertainties relating,
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our strategies, prospects, plans, expectations, forecasts
or objectives;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to commercialize our insulin pump products and
the costs and timing thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">acceptance of our products by our target market and our ability
to compete in such market;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to raise additional financing when needed and
the terms and timing thereof;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to expand, protect and maintain our intellectual
property rights;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our future operations, financial position, revenues, costs,
expenses, uses of cash, capital requirements, our need for additional financing or the period for which our existing cash resources will
be sufficient to meet our operating requirements;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our analysis of the target market for our insulin pump;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to obtain all regulatory approvals and clearances
relating to our insulin pump, including those of the FDA;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">regulatory developments in the United States and other countries;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the timing and costs of obtaining all regulatory approvals
and clearances required to market and sell our products;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our compliance with all applicable laws, rules and regulations,
including those of the SEC and the FDA;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to compete in the diabetes marketplace with larger
and more substantial medical device companies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">general economic, business, political and social conditions;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our reliance on and our ability to retain (and if necessary,
timely recruit and replace) our officers, directors and key employees and their ability to timely and competently perform at levels expected
of them;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to generate significant revenues and achieve
profitability;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to manage the growth of our business;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our commercialization, marketing and manufacturing capabilities
and strategies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to expand, protect and maintain our intellectual
property position;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the success of competing third-party products;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to meet the initial or continuing listing requirement
of the Nasdaq Capital Market;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to comply with regulatory requirements relating
to our business, and the costs of compliance with those requirements, including those on data privacy and security;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the specific risk factors discussed under the heading &ldquo;Risk
Factors&rdquo; set forth in this prospectus supplement; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">various other matters, many of which are beyond our control.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_006"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that our net proceeds from this offering
will be approximately $[&nbsp;&nbsp;&nbsp;], based on the public offering price of $ per two shares of common stock and accompanying warrant
and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently expect to use the net proceeds from
this offering primarily for working capital, capital expenditures and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our expected use of the net proceeds from this
offering represents our current intentions based upon our present plans and business conditions. As a result, our management will have
broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the
net proceeds of this offering. In addition, we might decide to postpone or not pursue these certain of these activities if the net proceeds
from this offering and the other sources of cash are less than, or do not last as long as, expected. We have no current understandings,
agreements or commitments for any material acquisitions or licenses of any products, businesses or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pending their use, we plan to invest the net proceeds
from this offering in high-quality, short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or
direct or guaranteed obligations of the U.S. government.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_007"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have never declared
or paid any cash dividend on our capital stock. We do not anticipate paying any cash dividends in the foreseeable future and we intend
to retain all of our earnings, if any, to finance our growth and operations and to fund the expansion of our business. Payment of any
dividends will be made in the discretion of our board of directors, after its taking into account various factors, including our financial
condition, operating results, current and anticipated cash needs and plans for expansion. Any dividends that may be declared or paid on
our common stock, must also be paid in the same consideration or manner, as the case may be, on our shares of preferred stock, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s_008"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you invest in our securities, your interest
will be diluted immediately to the extent of the difference between the combined offering price per two shares of our common stock and
accompanying warrant and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this
offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2025, our historical net tangible
book value, which represents our total tangible assets less total liabilities, was approximately $<FONT STYLE="background-color: white">8,769,000</FONT>,
or $<FONT STYLE="background-color: white">0.143</FONT> per share of common stock. Historical net tangible book value per share represents
the amount of our total tangible assets reduced by total liabilities, divided by <FONT STYLE="background-color: white">61,171,488</FONT>,
the number of shares of common stock outstanding on September 30, 2025.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After giving effect to the sale of the
                                                                                                                  securities, at the combined offering price of $ per two shares of our common stock and accompanying warrant, after deducting
                                                                                                                  estimated underwriting discounts and commissions and estimated offering expenses payable by us, but assuming no exercise of the
                                                                                                                  Pre-Funded Warrants and the warrants offered, our net tangible book value as of September 30, 2025 would have been $<FONT STYLE="background-color: white">[&nbsp;&nbsp;&nbsp;]</FONT>
                                                                                                                  or $<FONT STYLE="background-color: white">[&nbsp;&nbsp;&nbsp;]</FONT> per share of common stock. This amount represents an immediate
                                                                                                                  increase in net tangible book value of $<FONT STYLE="background-color: white">[&nbsp;&nbsp;&nbsp;]</FONT> per share to our existing
                                                                                                                  stockholders. Investors purchasing our common stock in this offering will have paid $<FONT STYLE="background-color: white">[&nbsp;&nbsp;&nbsp;]</FONT>
                                                                                                                  more than the as adjusted net tangible book value per share of common stock after this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table illustrates this dilution
on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%">Offering price per share <BR></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%"></TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"></TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Historical net tangible book value per share as of September 30, 2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.143</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Increase in net tangible book value per share attributable to new investors</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net tangible book value per share after the offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Dilution per share to new investors</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"></TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The dilution information discussed above is illustrative
only and may change based on the actual initial public offering price and other terms of this offering. The offering price per share is
based on a price of $ per set of two shares of common stock and one warrant to purchase one share of common stock and including $ per
warrant for each whole accompanying warrant, which is allocated between the two shares of common stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of our common stock to be
outstanding after this offering is based on <FONT STYLE="background-color: white">61,171,488</FONT> shares of our common stock outstanding as
of September 30, 2025, and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">3,073,186 shares of Common Stock reserved for issuance under
our Amended and Restated 2017 Equity Incentive Plan (the &ldquo;2017 Plan&rdquo;);</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">7,229,026 shares of Common Stock issuable upon the exercise
of options outstanding, with a weighted average exercise price of $2.44 per share;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">62,501 shares of Common Stock issuable upon vesting of restricted
stock units;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">767,796 shares of common stock issuable upon exercise of
warrants outstanding at $6.00 per share;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">5,449,478 shares of common stock issuable upon exercise of
warrants outstanding at $6.60 per share;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">484,006 shares of common stock issuable upon exercise of
warrants outstanding at $1.325 per share;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">1,837,983 shares of common stock issuable upon exercise of
warrants outstanding at $1.22 per share;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">381,540 shares of common stock issuable upon exercise of
warrants outstanding at $1.875 per share;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">2,373,790 shares of common stock issuable upon exercise of warrants outstanding at $1.12 per share;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">874,672 shares of common stock issuable upon exercise of
warrants outstanding at $1.40 per share; and</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&#9679;</TD><TD STYLE="text-align: justify">2,930,242 shares of common stock issuable upon exercise of warrants outstanding at $0.84 per share.</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the shares described above that are reserved
for issuance to the holders of our options and under our 2017 Plan are issued, or we otherwise issue additional shares of common stock
in the future, there could be further dilution to investors participating in this offering. In addition, we anticipate needing to raise
additional capital before generating positive cash flows and we may choose to raise additional capital because of market conditions or
strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional
capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to
our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_009"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are offering shares of common stock and warrants
to purchase shares of our common stock. This offering also includes the offer and sale of the shares of common stock issuable from time
to time upon exercise of the warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 8, 2025, we had 63,677,389 shares
of common stock issued and outstanding, 14,777,383 shares of common Stock issuable upon exercise of outstanding warrants, and 7,363,248
shares of common stock issuable under equity awards outstanding under the 2017 Plan.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of our certificate of incorporation,
holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including
the election of directors, and do not have cumulative voting rights. The holders of outstanding shares of common stock are entitled to
receive dividends out of assets or funds legally available for the payment of dividends of such times and in such amounts as our Board
of Directors from time to time may determine. Our common stock is not entitled to pre-emptive rights and is not subject to conversion
or redemption. Upon liquidation, dissolution or winding up of our company, the assets legally available for distribution to stockholders
are distributable ratably among the holders of our common stock after payment of liquidation preferences, if any, on any outstanding payment
of other claims of creditors. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected
by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following summary of certain terms and
provisions of the warrants that are being offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions
of the warrants, a form of which has been provided to the investors in this offering and which will be filed with the SEC as an exhibit
to a Current Report on Form 8-K in connection with this offering and incorporated by reference into the registration statement of which
this prospectus supplement forms a part. Prospective investors should carefully review the terms and provisions of the form of warrant
for a complete description of the terms and conditions of the warrants.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Duration and Exercise Price.</I> Each warrant
offered hereby will have an initial exercise price per share equal to $ . The warrants will be immediately exercisable and will expire
on the fifth anniversary of the original issuance date. The exercise price and number of shares of common stock issuable upon exercise
is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common
stock and the exercise price. The warrants will be issued separately from the common stock and may be transferred separately immediately
thereafter. One warrant to purchase one share of our common stock will be issued for every shares of common stock purchased in this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercisability</I>. The warrants will be exercisable,
at the option of each holder, in whole or in part, by delivering a duly executed exercise notice accompanied by payment in full for the
number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). A holder
(together with its affiliates) may not exercise any portion of the warrant to the extent that the holder would own more than 4.99% of
the outstanding common stock immediately after exercise, except that upon at least 61 days&rsquo; prior notice from the holder to us,
the holder may increase the amount of ownership of outstanding stock after exercising the holder&rsquo;s warrants up to 9.99% of the number
of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined
in accordance with the terms of the warrants. No fractional shares of common stock will be issued in connection with the exercise of a
warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cashless Exercise</I>. If, at the time a holder
exercises its warrants, a registration statement registering the issuance of the shares of common stock underlying the warrants under
the Securities Act is not then effective or available and an exemption from registration under the Securities Act is not available for
the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment
of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number
of shares of common stock determined according to a formula set forth in the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_010"></A>UNDERWRITING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Newbridge Securities Corporation (&ldquo;Newbridge&rdquo;
or the &ldquo;underwriter&rdquo;) is acting as sole underwriter of this offering. We entered into an underwriting agreement with Newbridge
with respect to the securities subject to this offering. Subject to the terms and conditions stated in the underwriting agreement dated
the date of this prospectus, the underwriter has agreed to purchase, and we have agreed to sell to the underwriter, the number of shares
of our common stock and warrants shown in the table below.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Underwriter</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<BR> Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of Warrants</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1.5pt">Newbridge Securities Corporation</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriting agreement provides that the obligations
of the underwriter to purchase the securities included in this offering are subject to approval of legal matters by counsel and to other
conditions. The underwriting agreement provides that the underwriter will purchase all of the securities if any of them are purchased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">securities sold by the underwriter to the public will initially be
offered at the combined public offering price set forth on the cover of this prospectus. In addition, the underwriter may offer some of
the securities to other securities dealers at such price less a concession of $ per combined public offering price per two shares of common
stock and accompanying warrant. After the initial offering of the securities, the combined public offering price or any other term of
the offering may be changed by the underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Underwriting discounts and commissions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows the effective public offering price per
share of common stock and accompanying warrant and total public offering price, underwriting discounts and commissions, and proceeds
before expenses to us.&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Effective<BR> Price Per<BR> Share of Common Stock and Accompanying Warrant</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<BR> Without<BR> Option</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total With<BR> Option</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%">Public offering price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">We have agreed to pay the underwriters a commission of 7.0% of the
gross proceeds of this offering.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Over-Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the discount set forth in the above
table, we have granted to the underwriters an option, exercisable not later than 30 days after the date of this prospectus, to purchase
up to a number of additional shares of common stock equal to 15% of the shares of common stock in this offering and/or a number of additional
warrants equal to 15% of the warrants sold in this offering, in any combination thereof, firmly committed in this offering at a price
of $[&nbsp;&nbsp;&nbsp;&nbsp;] per share or $[&nbsp;&nbsp;&nbsp;&nbsp;] per warrant to purchase one share of common stock, in each case,
less the underwriting discounts and commissions. The underwriters may exercise the option solely to cover over-allotments, if any, made
in connection with this offering. If any additional shares of our common stock and/or warrants are purchased pursuant to the over-allotment
option, the underwriters will offer these additional shares of our common stock and/or warrants on the same terms as those on which the
other shares of common stock and warrants are being offered hereby.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Underwriter&rsquo;s Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the closing of this offering, we have agreed
to issue to Newbridge, or its designees, warrants (the &ldquo;underwriter&rsquo;s warrants&rdquo;) to purchase a number of shares of common
stock equal to an aggregate of 7% of the total shares sold in this public offering. The underwriter&rsquo;s warrants will be exercisable
at a per share exercise price equal to 120% of the public offering price per share of common stock sold in this offering. The underwriter&rsquo;s
warrants are exercisable at any time and from time to time, in whole or in part, during the four-and-a-half-year period commencing six
months after the effective date of the registration statement related to this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter&rsquo;s warrants and the
shares of common stock issuable upon exercise of such warrants are not being registered in this prospectus. The underwriter&rsquo;s warrants and the shares of common stock
underlying the underwriter&rsquo;s warrants have been deemed compensation by the Financial Industry Regulatory Authority, or FINRA,
and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. Neither Newbridge or its permitted assignees
under such rule, may sell, transfer, assign, pledge, or hypothecate the underwriter&rsquo;s warrants or the securities underlying
the underwriter&rsquo;s warrants, nor will Newbridge engage in any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the underwriter&rsquo;s warrants or the underlying shares for a period of 180
days from the effective date of the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the underwriter&rsquo;s warrants
may not be sold, transferred, assigned, pledged or hypothecated for a 180-day period following the effective date of the registration
statement except to any underwriter and selected dealer participating in this offering and their bona fide officers or partners. The underwriter&rsquo;s
warrants will provide for adjustment in the number and price of the underwriter&rsquo;s warrants and the shares of common stock underlying
such underwriter&rsquo;s warrants in the event of recapitalization, merger, stock split or other structural transaction, or a future financing
undertaken by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Lock-Ups</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our officers and directors have agreed that, for a period of sixty (60)
days, from the date of this prospectus, they will not, subject to certain exceptions, offer, pledge, sell, contract to sell, sell any
option, right or warrant to purchase, lend or otherwise transfer or dispose, directly or indirectly, any shares of our capital stock or
any securities convertible into or exercisable or exchangeable for shares of capital stock without the prior written consent of Newbridge.
Additionally, we have also agreed that, for a period of ninety (90) days from the date of this prospectus, we will not, subject to certain
exceptions, offer, pledge, sell, contract to sell, sell any option, right or warrant to purchase, lend or otherwise transfer or dispose,
directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of
capital stock without the prior written consent of Newbridge. Newbridge, in its sole discretion, may release any of the securities subject
to these lock-up agreements at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nasdaq Capital Market Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on Nasdaq Capital Market under the symbol
&ldquo;MODD.&rdquo; There is no established trading market for the warrants, and we do not intend to apply for listing of the Warrants
on The Nasdaq Capital Market or on any national securities exchange. Without a trading market, the liquidity of the warrants will be extremely
limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Expenses and Reimbursements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that our portion of the total expenses
of this offering will be approximately $[&nbsp;&nbsp;&nbsp;&nbsp;], which includes the fees and expenses for which we have agreed to reimburse the underwriter,
including the fees and disbursements of counsel for the underwriter, in connection with the offering in an amount not to exceed $85,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Price Stabilization, Short Positions and Penalty
Bids</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until the distribution of shares of common stock
in this offering is complete, SEC rules may limit the ability of the underwriter to bid for and purchase shares of our common stock. As
an exception to these rules, underwriters are permitted to engage in certain transactions which stabilize the price of the shares of common
stock, which may include short sales, covering transactions and stabilizing transactions. Short sales involve sales of shares of common
stock in excess of the number of shares to be purchased by the underwriter in the offering, which creates a short position. &ldquo;Covered&rdquo;
short sales are sales made in an amount not greater than the underwriter&rsquo;s option to purchase additional shares of common stock
from us in the offering. An underwriter may close out any covered short position by either exercising its option to purchase additional
shares of common stock or purchasing shares of common stock in the open market. In determining the source of shares of common stock to
close out the covered short position, the underwriter will consider, among other things, the price of shares of common stock available
for purchase in the open market as compared to the share price at which the underwriter may purchase through its option to purchase additional
shares. &ldquo;Naked&rdquo; short sales are any sales in excess of such option. The underwriter must close out any naked short position
by purchasing shares of common stock in the open market. A naked short position is more likely to be created if the underwriter is concerned
that there may be downward pressure on the price of the shares of common stock in the open market after pricing that could adversely affect
investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of the shares of common stock
made by the underwriters in the open market prior to the completion of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter may also impose a penalty bid.
This occurs when a particular underwriter repays to another underwriter a portion of the underwriting discount received by it because
the representative has repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither we nor the underwriter make any representation
or prediction as to the direction or magnitude of any effect that the transactions described above might have on our shares of common
stock. Any of these activities may have the effect of preventing or retarding a decline in the market price of our shares of common stock.
They may also cause the price of the shares of common stock to be higher than the price that would otherwise exist in the open market
in the absence of these transactions. If an underwriter commences any of these transactions, it may discontinue them at any time without
notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect that delivery of the shares will be
made to investors on or about December [&nbsp;&nbsp;&nbsp;&nbsp;], 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the underwriter
or any securities dealers may distribute prospectuses by electronic means, such as e-mail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter is a full service financial institution
engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment
management, principal investment, hedging, financing and brokerage activities. The underwriter and its affiliates may, from time to time,
engage in transactions with and perform services for us in the ordinary course of its business for which it may receive customary fees
and reimbursement of expenses. In the ordinary course of its various business activities, the underwriter and its affiliates may make
or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments
(which may include bank loans and/or credit default swaps) for its own account and for the accounts of its customers and may at any time
hold long and short positions in such securities and instruments. Such investments and securities activities may involve securities and/or
instruments of ours or our affiliates. The underwriter and its affiliates may also make investment recommendations and/or publish or express
independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales Outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No action has been taken in any jurisdiction (except
in the United States) that would permit a public offering of our common stock or accompanying warrants, or the possession, circulation
or distribution of this prospectus or any other material relating to us or our common stock in any jurisdiction where action for that
purpose is required. Accordingly, the shares of common stock and accompanying warrants may not be offered or sold, directly or indirectly,
and neither this prospectus nor any other offering material or advertisements in connection with our common stock and accompanying warrants
may be distributed or published, in or from any country or jurisdiction, except in compliance with any applicable rules and regulations
of any such country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriter may arrange to sell the common
stock and accompanying warrants offered hereby in certain jurisdictions outside the United States, either directly or through affiliates,
where it is permitted to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_011"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the shares of common stock and
warrants offered by this prospectus supplement has been passed upon for us by Lucosky Bookman LLP, Woodbridge, New Jersey. McGuireWoods
LLP is acting as counsel for the underwriter in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="s_012"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial
statements of Modular Medical, Inc. as of and for the years ended March 31, 2025 and 2024 incorporated by reference in this Prospectus
supplement to the Annual Report on Form 10-K for the year ended March 31, 2025, have been so incorporated in reliance on the report of
Farber Hass Hurley LLP, an independent registered public accounting firm, as indicated in their report with respect thereto, and are included
herein in reliance upon the authority of said firm as experts in auditing and accounting in giving said report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><A NAME="s_013"></A><B>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate&rdquo;
into this prospectus supplement information that we file with the SEC in other documents. This means that we can disclose important information
to you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus
supplement is considered part of this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information contained in this
prospectus supplement and information that we file with the SEC in the future and incorporate by reference in this prospectus supplement
automatically modifies and supersedes previously filed information, including information in previously filed documents or reports that
have been incorporated by reference in this prospectus supplement, to the extent the new information differs from or is inconsistent with
the old information. Any statement so modified will be deemed to constitute a part of this prospectus supplement only as so modified,
and any statement so superseded will be deemed not to constitute a part of this prospectus supplement. For more information, see &ldquo;About
this Prospectus Supplement.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We incorporate by reference,
as of their respective dates of filing, the documents listed below that we have filed with the SEC and any additional documents that we
may file in the future with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the&nbsp;Exchange Act, including any documents filed
after the date on which the registration statement of which this prospectus supplement is a part is initially filed until the offering
of the security covered by this prospectus supplement has been completed, other than, in each case, documents or information deemed to
have been &ldquo;furnished&rdquo; and not &ldquo;filed&rdquo; in accordance with SEC rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390025055793/ea0244006-10k_modular.htm">Form
10-K</A> for the fiscal year ended March 31, 2025 filed with the SEC on June 20, 2025;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our Quarterly Reports on Form 10-Q for the quarters ended
<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390025076594/ea0252024-10q_modular.htm">June 30, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390025110819/ea0264284-10q_modular.htm">September 30, 2025</A>, filed with the SEC on August 14, 2025 and November 14, 2025, respectively;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our Current Reports on Form 8-K filed <A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390025048276/ea0243551-8k_modular.htm">May
28, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390025090336/ea0258326-8k_modular.htm">September 23, 2025</A>;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">All reports and other documents we subsequently file pursuant
to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such documents we may
file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement,
but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus
supplement and deemed to be part of this prospectus supplement from the date of the filing of such reports and documents.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby undertake to provide
without charge to each person, including any beneficial owner, to whom this prospectus supplement is delivered, upon written or oral request,
a copy of any or all documents that are incorporated by reference into this prospectus supplement, but not delivered with the prospectus
supplement, other than exhibits to such documents unless such exhibits are specifically incorporated by reference into this prospectus
supplement. These documents are also available free of charge through the investors section on our website at www.modular-medical.com
as soon as practicable after such materials have been electronically filed with, or furnished to, the SEC. You may request a copy of these
filings, at no cost, by writing or telephoning us at the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Modular Medical, Inc.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">10740 Thornmint Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(858) 800-3500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the
information contained in this prospectus supplement, in any accompanying prospectus supplement, or in any document incorporated by reference
herein or therein. We have not authorized anyone to provide you with any different information. We take no responsibility for, and can
provide no assurance as to the reliability of, any other information that others may provide to you. The information contained in this
prospectus supplement and in the documents incorporated by reference herein or therein is accurate only as of the date such information
is presented. Our business, financial condition, results of operations and future prospects may have changed since those respective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="s_014"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual, quarterly
and current reports and other information with the SEC. Our filings with the SEC are available from the SEC&rsquo;s website at www.sec.gov,
which contains reports, proxy and information statements, and other information regarding issuers that file electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement
and the accompanying prospectus are part of a registration statement that we filed with the SEC. As permitted by SEC rules, this prospectus
supplement and the accompanying prospectus form a part of the registration statement, but do not contain all of the information that is
included in the registration statement. The registration statement contains more information regarding us and our securities, including
certain exhibits. You can obtain a copy of the registration statement from the SEC&rsquo;s website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_003.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MODULAR MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>$75,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus will allow us to issue, from time to time at prices and on terms to be determined at or prior to the time of the offering,
up to $75,000,000 of any combination of the securities described in this prospectus, either individually or in units. We may also offer
common stock or preferred stock upon conversion of or exchange for the debt securities; and common stock or preferred stock or debt securities
upon the exercise of warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus describes the general terms of these securities and the general manner in which these securities will be offered. We will provide
you with the specific terms of any offering in one or more supplements to this prospectus. The prospectus supplements will also describe
the specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document.
You should read this prospectus and any prospectus supplement, as well as any documents incorporated by reference into this prospectus
or any prospectus supplement, carefully before you invest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
securities may be sold directly by us to you, through agents designated from time to time or to or through underwriters or dealers. For
additional information on the methods of sale, you should refer to the section entitled &ldquo;Plan of Distribution&rdquo; in this prospectus
and in the applicable prospectus supplement. If any underwriters or agents are involved in the sale of our securities with respect to
which this prospectus is being delivered, the names of such underwriters or agents and any applicable fees, commissions or discounts and
over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds that
we expect to receive from such sale will also be set forth in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
common stock is listed on the Nasdaq Capital Market, under the symbol &ldquo;MODD.&rdquo; On May 12, 2025, the last reported sale price
of our common stock was $1.02 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>Investing
in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the
risks that we have described on page 6</B>&nbsp;<B>of this prospectus under the caption &ldquo;Risk Factors.&rdquo; We may include specific
risk factors in supplements to this prospectus under the caption &ldquo;Risk Factors.&rdquo; This prospectus may not be used to sell our
securities unless accompanied by a prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">The date of this prospectus
is May 22, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_002"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_003"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_004"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_005"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_006"><FONT STYLE="font-size: 10pt">GENERAL DESCRIPTION OF SECURITIES</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">9-14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_007"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_008"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_009"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#p_010"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#p_011"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 24; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="p_001"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a &ldquo;shelf&rdquo;
registration process. Under this shelf registration process, we may offer shares of our common stock, preferred stock, various series
of debt securities or warrants to purchase common stock or preferred stock, either individually or in units, in one or more offerings,
with a total value of up to $75,000,000. This prospectus provides you with a general description of the securities we may offer. Each
time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will contain specific
information about the terms of that offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering
of the securities, you should refer to the registration statement, including its exhibits. The prospectus supplement may also add, update
or change information contained or incorporated by reference in this prospectus. However, no prospectus supplement will offer a security
that is not registered and described in this prospectus at the time of its effectiveness. This prospectus, together with the applicable
prospectus supplements and the documents incorporated by reference into this prospectus, includes all material information relating to
the offering of securities under this prospectus. You should carefully read this prospectus, the applicable prospectus supplement, the
information and documents incorporated herein by reference and the additional information under the heading &ldquo;Where You Can Find
More Information&rdquo; before making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">You
should rely only on the information we have provided or incorporated by reference in this prospectus or any prospectus supplement. We
have not authorized anyone to provide you with information different from that contained or incorporated by reference in this prospectus.
No dealer, salesperson or other person is authorized to give any information or to represent anything not contained or incorporated by
reference in this prospectus. You must not rely on any unauthorized information or representation. This prospectus is an offer to sell
only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that
the information in this prospectus or any prospectus supplement is accurate only as of the date on the front of the document and that
any information we have incorporated herein by reference is accurate only as of the date of the document incorporated by reference, regardless
of the time of delivery of this prospectus or any sale of a security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document
that is incorporated by reference in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including,
in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly,
such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
prospectus may not be used to consummate sales of our securities, unless it is accompanied by a prospectus supplement. To the extent there
are inconsistencies between any prospectus supplement, this prospectus and any documents incorporated by reference, the document with
the most recent date will control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unless
the context otherwise requires, &ldquo;Modular Medical,&rdquo; &ldquo;the Company,&rdquo; &ldquo;the Registrant,&rdquo; &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; and similar terms refer to Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="p_002"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights
selected information that is presented in greater detail elsewhere in this prospectus or incorporated by reference in this prospectus.
Because it is only a summary, it does not contain all of the information you should consider before investing in our securities, and it
is qualified in its entirety by, and should be read in conjunction with, the more detailed information included elsewhere in this prospectus.
Before you decide whether to purchase our securities, you should read this entire prospectus, the applicable prospectus supplement and
any related free writing prospectus carefully, including the risks of investing in our securities discussed under the heading &ldquo;Risk
Factors&rdquo; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in
the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated
by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus
is a part.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a pre-revenue medical
device company focused on the design, development and commercialization of innovative insulin pumps using modernized technology to increase
pump adoption in the diabetes marketplace. Through the creation of a novel two-part patch pump, our initial product, the MODD1, and its
successor tubeless product, the Pivot, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher
standards of care that presently available insulin pumps provide. By simplifying and streamlining the user experience from introduction,
prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly
motivated &ldquo;super users&rdquo; and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly
growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, we submitted a 510(k) premarket notification
to the United States Food and Drug Administration (the &ldquo;FDA&rdquo;) for our MODD1 insulin pump, and, in September 2024, we received
FDA clearance to market and sell our MODD1 pump in the United States. We are actively working to commercialize our MODD1 product and commence
initial shipments in the first half of fiscal 2026, obtain regulatory clearance to market and sell our MODD1 product in foreign jurisdictions,
improve the manufacturability and usability of our MODD1 product and submit the Pivot tubeless version of the product for FDA approval
during the quarter ending September 30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Differentiation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that there are
a number of shortcomings and issues with currently available insulin pumps that prevent a substantial number of people who require insulin
on a daily basis from choosing an insulin pump to treat their diabetes. We believe, that by tailoring our insulin pump to address such
factors, we can expand the scope and adoption rate of insulin pump usage. We believe that to achieve broader market acceptance, an insulin
pump must be easier to learn to use, be less time- consuming to operate, more intuitive to both patients and physicians, and meet the
standards for coverage by insurance providers so that co-payments required from patients are affordable and the hurdles to insurance coverage
are significantly reduced, all while not compromising accuracy and the basal bolus ability of a true pump.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Among the more prominent issues
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Complexity</I>: Many existing
pumps are highly complex and require significant technical expertise to use effectively. We believe such pumps were designed for &ldquo;super
users,&rdquo; who have high levels of motivation and technical competence. The complexity of pumps may be daunting to less technically
inclined, less motivated users.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Cumbersome</I>: We believe that a majority of existing pumps are bulky and difficult to manage, requiring a means of carrying the pump around and up to 48 inches of tubing to the injection site to connect the catheter to a pump. The tubing and the cartridge, which holds the insulin, must be replaced every few days. This requires users to carry spare parts and other equipment adding to the difficulty of using the pump. In comparison, our product only requires a cartridge change every few days.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Cost</I>: Costs associated with insulin pump therapy can be high and prohibitive, especially for those on fixed or limited incomes. These costs vary by pump and insurance coverage, but multi-thousand-dollar upfront payments, often with substantial co-payments in addition to possible additional co-payments on consumables, can easily place current pumps out of reach for patients. The leading patch pump on the market today also requires the user to discard all the electronics required for pumping and communication every three days, creating a higher cost architecture. This leads to limited or absent reimbursement/coverage and potentially high financial hurdles for patients to gain access.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Outdated style</I>: Consumer electronics devices have evolved in both form and function. Diabetes pumps have not experienced similar progress. We believe that consumers will be more receptive of products designed with the user experience in mind and that many have low tolerance for complex, difficult procedures for use and maintenance of products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Pump mechanism limitations</I>: Traditional pumps generally utilize a syringe and plunger mechanism to deliver insulin. We believe this design limits the ability to reduce the size of the pump, and also potentially exposes the user to the unintended delivery of the full volume of insulin within the pump, which can cause hypoglycemia or death. We believe that the fear of adverse health events due to technical malfunctions related to traditional pump mechanism limitations deters the adoption of insulin pump therapy.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our team has substantial knowledge
of the diabetes industry and experience in developing, obtaining marketing authorization for, and bringing insulin pumps to market. Based
on this experience, we believe that our innovative insulin pump, using a new and proprietary method of pumping insulin, can address most
or all of these shortcomings. It provides a state-of-the-art insulin pump capable of both basal (steady flow) and bolus (mealtime dosing)
insulin disbursement. It also has been designed considering a natural migration path to multi-chamber/multi-liquid pumps, potentially
offering an exciting array of new therapies to patients with diabetes and other conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our goal is to become the
leader in expanding access to insulin pump technology to a wider portion of diabetes sufferers and provide not just care for the super
users, but &ldquo;diabetes care for the rest of us.&rdquo; While our initial target market is people with Type 1 diabetes, we believe
there is a substantial opportunity to penetrate the type 2 marketplace, first through our initial MODD1 pump, and with the future introduction
of Pivot making our pump the only 3 milliliter, tubeless removable patch pump on the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The MODD1, and its successor
product the Pivot, are high-precision pumps that we believe represent the best choice for new pump patients because the products will
be easy to afford, easy to learn, easy to use, and have a revolutionary design and technology that enable precision with low-cost manufacture
and high reproducibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Key features include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Two parts - one reusable, one disposable - snap together to form the working system;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">One button interface, easy to learn and use;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">90-day reusable, 3-day disposable;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Disposable portion removable at any time from an adhesive-backed retainer, which remains in place;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">No external controller required, no charging, no battery replacement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Slim profile, lighter weight.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A proprietary survey of American
healthcare payors representing 50 million covered lives (approximately 1/3 of U.S. covered lives) performed for us by industry leading
survey firm ISA in 2019 has demonstrated that payors are willing to grant equivalent or preferential coverage for a product with this
feature set at launch in exchange for discounts of approximately 20%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, along with marketplace
data provided by Seagrove Partners in 2023, estimates that 33% of Americans with Type 1 diabetes, or T1D, have an insulin pump and 28%
of Americans with T1D (44% of those who currently utilize MDI) can be classified as having an interest in pump adoption and meeting the
American Diabetes Association guidelines of glucose control if their objections to the currently available suite of products can be overcome.
They do not want to closely manage their glucose levels and incur the associated time and effort involved. They are the Almost Pumpers.
We have developed what we believe to be the most technologically advanced delivery system to overcome the objections and provide the needed
motivation for this market to develop. We believe that there are four addressable hurdles to adoption:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Usability: the device needs to be easy to learn and to operate;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Affordability: we will focus on overcoming copay and insurance hurdles rather than leaving the &ldquo;insurance journey&rdquo; to the clinician and patient;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Accessibility and Education: we will seek to engage patients to sample this new technology by supplying clinicians with free samples and simple training to allow people to see first-hand the typical barriers to adoption that have been overcome; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Service and Support: where we will answer their questions and concerns during this diabetes experience.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe this conversion
process, engaging people to try and thereby receive the benefits of our technology will substantially increase adoption of insulin pumps
among both those with T1D and Type 2 diabetes who remain reliant upon multiple daily injections. Diabetes is a disease that appears throughout
the world. Therefore, we cannot segment the market by socioeconomics, education or level of care. We intend to create an insulin pump
that appeals to all Almost Pumpers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Insulin Pump</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Instead of building complex,
bespoke, and difficult to manufacture and maintain pumping and control systems, we began with the technology and the user in mind. Using
proprietary and patented methods of insulin measurement, we were able to eschew complex mechanisms and instead built a product candidate
using only parts from high volume consumer electronics manufacturing lines, breaking the cost vs functionality curve that has existed
in the insulin pump space and representing the first truly modern insulin pump design. This is a new kind of product for a new kind of
patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A good part of our focus has
shifted to managing the process of preparing to move our initial production line to our manufacturing partner, Phillips-Medisize, a large
tier-one medical device manufacturer, which will manage and operate our production to produce products for human use. We believe that
Phillips-Medisize will be able to rapidly scale to higher volumes at lower cost. We continue to devote substantial time and resources,
including exhibiting at major diabetes conferences, to better understand the needs and preferences of Almost Pumpers and the specific
patient/provider/payor requirements to motivate change from MDI therapy. By making the bolus delivery at meals simple, we believe we will
drive improved health outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">MODD1 has several distinguishing
features:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The pump has a simple button
to press to deliver insulin as the patient requires it. The electronic pump uses a simple motor and rotating cam to motivate the insulin
into the patient along with a low power Bluetooth and near-field communication (NFC) chips to optionally allow the patient to communicate
with their smart phone, tablet, or other mobile computing platform.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The pump snaps together with
a three-day disposable cartridge that is patient filled with insulin for delivery. It includes the power source and a simple coin cell
that allows it to run through the 80-hour life of the cartridge.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The infusion set contains a
soft 6 mm cannula and an introducer for insertion into the skin and removal of the needle used to transfer insulin to the body.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The system will deliver a
small continuous rate called a basal that will provide approximately 50% of the total daily dose required and the user will use the on-pump
button to administer boluses, typically before and after meals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The objective is to make the
product candidate simple to acquire and take home, simple to learn and most importantly, simple to use to expand the pump market, drive
adoption and ultimately better clinical outcomes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have developed a successor
product, the Pivot, which represents a new and improved version of the MODD1 and eliminates the external infusion set and incorporates
it into the adhesive plate, while maintaining the removable aspect of the pump. We anticipate that we will submit this product for FDA
approval in the fall of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Commercialization Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to commercialize our
MODD1 product line using a highly differentiated go-to-market strategy. Generally, current pumps are marketed by a large, direct sales
force to end users directly, and the manufacturer provides all training and support, as the current training reimbursement offered by
insurance providers is inadequate to motivate clinicians to provide such training to patients. We intend to employ a different strategy
and utilize i) distributors to target the daily insulin users who are still managed by a primary care physician and ii) a small direct
sales force to directly engage with diabetes educator practices. Specifically, our direct sales force will engage with larger diabetes
educator practices, which currently prescribe a high volume of pumps and deliver a consultative message focused on those users that indicate
a desire to use a pump but have rejected all of the currently available options. We engaged Seagrove Partners, LLC to conduct a survey
of physicians and diabetes educators, and the resulting data suggested that approximately 25% of multiple daily injectors could be receptive
to our offering. We believe that the modest 30-minute training requirement for our product, combined with the more limited feature set
for our MODD1, will incentivize nurse practitioners to identify and train new users who have not been offered pumps before. This would
also allow us to offer virtual or second level training support and not require us to be the primary training provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to launch our MODD1
product during the quarter ending September 30, 2025 in a single region in the United States with a select group of providers to gain
user experience. During the quarter ending December 31, 2025, we plan to submit a 510(k) premarket notification to the FDA for a new and
improved version of the MODD1 product, our Pivot product, which will use our proprietary, integrated insulin-delivery set manufactured
by us. We believe the new integrated insulin-delivery set will offer improved user experience, while reducing our production costs. The
Pivot pump is the version that we plan to launch nationally in the United States after we receive FDA clearance, which we expect could
occur during the quarter ending March 31, 2026.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also begun the process
of obtaining&nbsp;<I>Conformite Europeenne</I>, or CE, mark clearance for our Pivot pump, which would allow us to market and sell in European
markets. We expect to obtain CE mark clearance during the quarter ending March 31, 2026. Our initial strategy to address European markets
is to partner with distributors to bring the Pivot to market in those countries that accept the CE mark and have acceptable reimbursement.
We believe that the combination of our patch pump form factor, lower cost at scale and lower training burden is well suited for European
markets where there are very few physicians or nurses available to provide training. This would allow the Pivot to gain rapid adoption
in areas where pump penetration is currently much lower than in the United States. We will target other select international markets using
the same approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the combination
of these differentiated approaches will enable us to take reasonable initial market share, while not incurring the significant overhead
cost of existing commercialization strategies employed by the incumbents, where competition for users is intense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive offices
are located at 10740 Thornmint Road, San Diego, California 92127 and our telephone number is (858) 800-3500. We maintain a website at
www.modular-medical.com to which we regularly post copies of our press releases, as well as additional information about us. Our filings
with the Securities and Exchange Commission, or SEC, will be available free of charge through the website as soon as reasonably practicable
after being electronically filed with or furnished to the SEC. Information contained on, or accessible through, our website does not constitute
a part of this prospectus or our other filings with the SEC, and you should not consider any information contained on, or that can be
accessed through, our website as part of this prospectus or in deciding whether to purchase our Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All brand names or trademarks
appearing in this prospectus are the property of their respective holders. Use or display by us of other parties&rsquo; trademarks, trade
dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of,
us by the trademark or trade dress owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="p_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Investment in any securities
offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider the risk factors
incorporated by reference to our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current Reports
on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus,
as updated by our subsequent filings under the&nbsp;Exchange Act, and the risk factors and other information contained in the applicable
prospectus supplement before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part
of your investment in the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="p_004"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus, any accompanying
prospectus supplement, and the documents incorporated by reference herein and therein, include forward-looking statements within the meaning
of Section 27A of the&nbsp;Securities Act of 1933, as amended, or the&nbsp;Securities Act, and Section 21E of the&nbsp;Securities Exchange
Act of 1934, as amended, or the&nbsp;Exchange Act. All statements other than statements of historical fact contained in this prospectus,
any accompanying prospectus supplement, or the documents incorporated by reference herein or therein, including statements regarding estimates,
future events, our future financial performance, business strategy and plans and objectives of management for future operations, including
with respect to us specifically and the cancer diagnostics industry in general, are forward-looking statements. We have attempted to identify
estimates and forward-looking statements by terminology including &ldquo;aims,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;goal,&rdquo; &ldquo;intends,&rdquo;
&ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;predicts,&rdquo; &ldquo;seeks,&rdquo; &ldquo;should,&rdquo; &ldquo;suggests,&rdquo;
&ldquo;targets&rdquo; or &ldquo;will&rdquo; or the negative of these terms or other comparable terminology. Although we do not make estimates
or forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Our estimates
and forward-looking statements are based on our current assumptions and expectations about future events and trends, which affect or may
affect our business, strategy, operations or financial performance. These statements are only predictions and involve known and unknown
risks, uncertainties and other factors, which may cause our or our industry&rsquo;s actual results, levels of activity, performance or
achievements to vary materially from those expressed or implied by these estimates and forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Factors that could cause or
contribute to such differences in results and outcomes include, but are not limited to, those discussed under the section entitled &ldquo;Risk
Factors&rdquo; in this prospectus, any accompanying prospectus supplement, and in any documents incorporated by reference herein and therein.
Readers should carefully review this information as well as other risks and uncertainties described in other filings with the SEC that
we may make after the filing date of this prospectus. See the information included under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we operate in a
very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for us to predict all risk
factors, nor can we address the impact of all factors on our business or the extent to which any factor, or combination of factors, may
cause our actual results to differ materially from those contained in any estimates or forward-looking statements. All estimates and forward-looking
statements speak only as of the date they were made, and, except to the extent required by applicable law or regulation, we undertake
no obligation to update or to review any estimate and/or forward-looking statement. In light of these risks and uncertainties, we cannot
assure you that the estimates or forward-looking statements contained in this prospectus, any accompanying prospectus supplement, or the
documents incorporated by reference herein or therein, will in fact occur. You should not place undue reliance on these estimates and
forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We qualify all of our forward-looking
statements by these cautionary statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="p_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to use the net proceeds
we receive from the sale of our securities offered by us hereby for working capital and other general corporate purposes, including capital
expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
may set forth additional information regarding the use of proceeds from the sale of securities we offer under this prospectus in a prospectus
supplement relating to the specific offering. We have not determined the amount of net proceeds to be used specifically for the foregoing
purposes. As a result, our management will have broad discretion in the allocation of net proceeds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="p_006"></A><B>GENERAL DESCRIPTION OF SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We,
directly or through agents, dealers or underwriters designated from time to time, may offer, issue and sell, together or separately, in
one or more offerings, up to $75,000,000 in the aggregate, inclusive of any exercise price thereof, of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR>
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">shares of our common stock, par value $0.001 per share;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">shares of our preferred stock, par value $0.001 per share;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">debt securities;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">warrants to purchase shares of our common stock;</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">units comprised of one or more shares of common stock and warrants in any combination; or</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">any combination of the foregoing, each on terms to be determined at the time of sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The common stock, preferred
stock, debt securities, warrants and units are collectively referred to herein as the securities. This prospectus provides you with a
general description of the securities we may offer. Each time we offer securities under this prospectus, we will, to the extent required
by law, provide you with a prospectus supplement that will contain specific information about the terms of the offering. The prospectus
supplement may also add, update or change information in this prospectus. The securities involve various risks that we will describe in
the section entitled &ldquo;Risk Factors&rdquo; that will be included in each prospectus supplement. For more details, see the information
included under the heading &ldquo;About this Prospectus.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are authorized to issue up to 100,000,000 shares
of Common Stock, par value $0.001 per share and up to 5,000,000 shares of preferred stock, par value $0.001 per share. As of May 12, 2025,
there were 54,247,388 shares of our Common Stock outstanding. In addition, as of May 12, 2025, there were outstanding:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">5,397,871 shares of Common Stock reserved for issuance under our Amended and Restated 2017 Equity Incentive Plan;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">4,917,090 shares of Common Stock issuable upon the exercise of options outstanding, with a weighted average exercise price of $3.17 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">104,168 shares of Common Stock issuable upon vesting of restricted stock units;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">767,796 shares of Common Stock issuable upon exercise of warrants outstanding at $6.00 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">5,449,478 shares of Common Stock issuable upon exercise of warrants outstanding at $6.60 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">484,006 shares of Common Stock issuable upon exercise of warrants outstanding at $1.325 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3,564,183 shares of Common Stock issuable upon exercise of warrants outstanding at $1.22 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">381,540 shares of Common Stock issuable upon exercise of warrants outstanding at $1.875 per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">6,508,073 shares of Common Stock issuable upon exercise of warrants outstanding at $1.12 per share; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">874,672 shares of Common Stock issuable upon exercise of warrants outstanding at $1.40 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
is a summary, does not purport to be complete and is subject to and qualified in its entirety by reference to our amended and restated
articles of incorporation, and our amended bylaws, each of which is incorporated herein by reference and are exhibits to the registration
statement of which this prospectus forms a part. We encourage you to read our amended and restated articles of incorporation, our amended
bylaws and the applicable provisions of the Nevada Revised Statutes (the &ldquo;NRS&rdquo;) for additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each holder of our Common
Stock is entitled to a pro rata share of any cash distributions made to shareholders, including any dividend payments. The holders of
our Common Stock are entitled to one vote for each share or record on all matters to be voted on by our shareholders. There is no cumulative
voting with respect to the election of our directors or any other matter. Therefore, under our charter documents, the holders of more
than 50% of the shares voted for the election of those directors can elect all of the directors. Our board of directors currently are
elected as a single class. Our board of directors may from time to time declare dividends on our outstanding shares. In the event of our
liquidation, dissolution or winding up, the holders of our Common Stock are entitled to share ratably in all assets remaining available
for distribution to them after payment of our liabilities and after provision has been made for each class of stock, if any, having any
preference in relation to our Common Stock. Holders of shares of our Common Stock have no conversion, preemptive or other subscription
rights, and there are no redemption provisions applicable to our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our articles of incorporation
provide that our board of directors has the right in its discretion to issue preferred stock without approval of our shareholders and
to set the series, classes, rights, privileges and preferences of our preferred stock or any classes, or series thereof without approval.
In the event of a hostile takeover, the board of directors could potentially use this preferred stock to preserve control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our Common Stock is Colonial Stock Transfer Company, Inc., 7840 S 700 E, Sandy, UT 84070. Its telephone number is 801-355-5740.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Stock Market Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
common stock is listed on The Nasdaq Capital Market under the symbol &ldquo;MODD.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>DESCRIPTION OF DEBT
SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following description, together with the additional information we include in any applicable prospectus supplements, summarizes the material
terms and provisions of the debt securities that we may offer under this prospectus. While the terms we have summarized below will apply
generally to any future debt securities we may offer pursuant to this prospectus, we will describe the particular terms of any debt securities
that we may offer in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any
debt securities offered under such prospectus supplement may differ from the terms we describe below, and to the extent the terms set
forth in a prospectus supplement differ from the terms described below, the terms set forth in the prospectus supplement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
may sell from time to time, in one or more offerings under this prospectus, debt securities, which may be senior or subordinated. We will
issue any such senior debt securities under a senior indenture that we will enter into with a trustee to be named in the senior indenture.
We will issue any such subordinated debt securities under a subordinated indenture, which we will enter into with a trustee to be named
in the subordinated indenture. We use the term &ldquo;indentures&rdquo; to refer to either the senior indenture or the subordinated indenture,
as applicable. The indentures will be qualified under the&nbsp;Trust Indenture Act of 1939, as in effect on the date of the indenture.
We use the term &ldquo;debenture trustee&rdquo; to refer to either the trustee under the senior indenture or the trustee under the subordinated
indenture, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indentures are subject
to, and qualified in their entirety by reference to, all the provisions of the indenture applicable to a particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Each
indenture will provide that debt securities may be issued from time to time in one or more series and may be denominated and payable in
foreign currencies or units based on or relating to foreign currencies. Neither indenture will limit the amount of debt securities that
may be issued thereunder, and each indenture will provide that the specific terms of any series of debt securities shall be set forth
in, or determined pursuant to, an authorizing resolution and/or a supplemental indenture, if any, relating to such series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
will describe in each prospectus supplement the following terms relating to a series of debt securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="width: 24px; padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the title or designation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the aggregate principal amount and any limit on the amount that may be issued;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the currency or units based on or relating to currencies in which debt securities of such series are denominated and the currency or units in which principal or interest or both will or may be payable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">whether we will issue the series of debt securities in global form, the terms of any global securities and who the depositary will be;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the maturity date and the date or dates on which principal will be payable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the date or dates interest will be payable and the record dates for interest payment dates or the method for determining such dates;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the terms of the subordination of any series of subordinated debt;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the place or places where payments will be payable;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional redemption provisions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund provisions or otherwise, to redeem, or at the holder&rsquo;s option to purchase, the series of debt securities;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">whether the indenture will restrict our ability to pay dividends, or will require us to maintain any asset ratios or reserves</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 48px">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify; width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">whether we will be restricted from incurring any additional indebtedness;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">a discussion on any material or special U.S. federal income tax considerations applicable to a series of debt securities;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt; width: 48px">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify; width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt; text-align: justify"><FONT STYLE="font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of
acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax
considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
will set forth in the prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable
for our common stock or our other securities. We will include provisions as to whether conversion or exchange is mandatory, at the option
of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities
that the holders of the series of debt securities receive would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Information Concerning the Debenture Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
debenture trustee, other than during the occurrence and continuance of an event of default under the applicable indenture, undertakes
to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the
debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use in the conduct of his
or her own affairs. Subject to this provision, the debenture trustee is under no obligation to exercise any of the powers given it by
the indentures at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs,
expenses and liabilities that it might incur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Unless
we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest
payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business
on the regular record date for the interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated
by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check which
we will mail to the holder. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the
debenture trustee in the City of New York as our sole paying agent for payments with respect to debt securities of each series. We will
name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular
series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All
money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities
which remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to
us, and the holder of the security thereafter may look only to us for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
indentures and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the
extent that the&nbsp;Trust Indenture Act&nbsp;is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Subordination of Subordinated Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to
certain of our other indebtedness to the extent described in a prospectus supplement. The subordinated indenture does not limit the amount
of senior indebtedness we may incur. It also does not limit us from issuing any other secured or unsecured debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
may offer, sell and issue, from time to time, warrants to purchase shares of our common stock. The warrants may be issued independently
or together with shares of our common stock and may be attached to or separate from the shares of our common stock. If we issue warrants,
they will be evidenced by warrant agreements or warrant certificates issued under one or more warrant agreements, which will be contracts
between us and/or a bank or trust company, as warrant agent, and the holders of the warrants or an agent for the holders of the warrants,
all as shall be set forth in the prospectus supplement relating to warrants being offered pursuant to such prospectus supplement. The
forms of warrant agreements or warrant certificates, as applicable, relating to the warrants will be filed as exhibits to the registration
statement of which this prospectus is part and/or will be incorporated by reference from reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference
to, all of the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. We urge you
to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant
certificates that contain the terms of the warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Whenever
warrants are to be issued and sold pursuant to this prospectus, we will file a prospectus supplement relating to that offer and sale which
will specify (in each case as applicable):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of shares of common stock purchasable upon exercise of the warrants and the exercise price at which such number of shares may be purchased upon exercise;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the price or prices at which the warrants will be issued;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the provisions, if any, for changes to or adjustments in the exercise price;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the provisions, if any, for call rights or put rights relating to the warrants or the underlying shares of common stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the date on which the right to exercise the warrants shall commence and the date on which the right will expire;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if applicable, the number of warrants issued with each share of our common stock;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">if applicable, the date on and after which the warrants and the related common stock will be separately transferable; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other terms of the warrants, including terms, procedures and limitations relating to the exchange, exercise and settlement of the warrants.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until any warrants to purchase
common stock are exercised, the holders of warrants will not be entitled, by virtue of being such holders, to vote, consent, receive dividends,
receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter, or to
exercise any rights whatsoever as our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each warrant will entitle
the holder to purchase for cash such shares of our common stock at such exercise price as shall be in each case be set forth in, or be
determinable as set forth in, the prospectus supplement relating to the warrants offered thereby. Warrants may be exercised at any time
up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After
the close of business on the expiration date, unexercised warrants will become void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants may be exercised
as set forth in the prospectus supplement relating to the warrants offered. Upon receipt of payment and the warrant certificate properly
completed and duly executed at the Company or the corporate trust office of the warrant agent, as applicable, or any other office indicated
in the prospectus supplement, we will, as soon as practicable, forward the shares of our common stock purchasable upon such exercise.
If less than all of the warrants represented by such warrant certificate are exercised, a new warrant certificate will be issued for the
remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may issue units comprised
of one or more of the other securities described in this prospectus in any combination from time to time. Each unit will be issued so
that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights
and obligations of a holder of each included security. If we issue units, they will be evidenced by unit agreements or unit certificates
issued under one or more unit agreements, which will be contracts between us and the holders of the units or an agent for the holders
of the units. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or
transferred separately, at any time or at any time before a specified date. The forms of unit agreements or unit certificates, as applicable,
relating to the units will be filed as exhibits to the registration statement that includes this prospectus, or as an exhibit to a filing
with the SEC that is incorporated by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="p_007"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may sell our securities
from time to time in any manner permitted by the&nbsp;Securities Act, including any one or more of the following ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">to investors through agents;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">directly to agents;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">to or through underwriters;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">to or through broker-dealers (acting as agent or principal);</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in a block trade;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in ordinary brokerage transactions and transactions in which a broker solicits purchasers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in privately negotiated transactions;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in &ldquo;at the market&rdquo; offerings, within the meaning of&nbsp;Rule 415(a)(4) of the&nbsp;Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise; and/or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">directly to purchasers, through a specific bidding or auction process or otherwise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The securities may be sold
at a fixed price or prices, which may be changed, at market prices prevailing at the time of sale, at prices relating to the prevailing
market prices or at negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Offers to purchase offered
securities may be solicited by agents designated by us from time to time. Any agent involved in the offer or sale of the offered securities
in respect of which this prospectus is delivered will be named, and any commissions payable by us will be set forth, in the applicable
prospectus supplement. Unless otherwise set forth in the applicable prospectus supplement, any agent will be acting on a reasonable best
efforts basis for the period of its appointment. Any agent may be deemed to be an underwriter, as that term is defined in the&nbsp;Securities
Act, of the offered securities so offered and sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will set forth in a prospectus
supplement the terms of the offering of our securities, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the name or names of any agents, underwriters or dealers;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the purchase price of our securities being offered and the proceeds we will receive from the sale;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any over-allotment options under which underwriters may purchase additional securities from us;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any agency fees or underwriting discounts and commissions and other items constituting agents&rsquo; or underwriters&rsquo; compensation;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">the public offering price;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any discounts or concessions allowed or reallowed or paid to dealers; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">any securities exchanges on which such securities may be listed.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If offered securities are
sold to the public by means of an underwritten offering, either through underwriting syndicates represented by managing underwriters or
directly by the managing underwriters, we will execute an underwriting agreement with an underwriter or underwriters, and the names of
the specific managing underwriter or underwriters, as well as any other underwriters, will be set forth in the applicable prospectus supplement.
In addition, the terms of the transaction, including commissions, discounts and any other compensation of the underwriters and dealers,
if any, will be set forth in the applicable prospectus supplement, which prospectus supplement will be used by the underwriters to make
resales of the offered securities. If underwriters are utilized in the sale of the offered securities, the offered securities will be
acquired by the underwriters for their own account and may be resold from time to time in one or more transactions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">transactions on the Nasdaq Capital Market or any other organized market where the securities may be traded;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in the over-the-counter market;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">in negotiated transactions; or</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">under delayed delivery contracts or other contractual commitments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may grant to the underwriters
options to purchase additional offered securities to cover over-allotments, if any, at the public offering price with additional underwriting
discounts or commissions, as may be set forth in the applicable prospectus supplement. If we grant any over-allotment option, the terms
of the over-allotment option will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may authorize agents or
underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price
set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in
the future. We will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in
the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may indemnify agents, underwriters
and dealers against specified liabilities, including liabilities incurred under the&nbsp;Securities Act, or to contribution by us to payments
they may be required to make in respect of such liabilities. Agents, underwriters or dealers, or their respective affiliates, may be customers
of, engage in transactions with or perform services for us or our respective affiliates, in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise specified
in the applicable prospectus supplement, each class or series of securities will be a new issue with no established trading market, other
than our common stock, which is traded on the Nasdaq Capital Market. We may elect to list any other class or series of securities on any
exchange and, in the case of our common stock, on any additional exchange. However, unless otherwise specified in the applicable prospectus
supplement, we will not be obligated to do so. It is possible that one or more underwriters may make a market in a class or series of
securities, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. We cannot
give any assurance as to the liquidity of the trading market for any of the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any underwriter may engage
in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in accordance with&nbsp;Regulation M&nbsp;under
the&nbsp;Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions
permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering
or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment option or in the
open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession
from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short
positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters
may discontinue any of the activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To comply with the securities
laws of certain states, if applicable, the securities offered by this prospectus will be offered and sold in those states only through
registered or licensed brokers or dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In compliance with guidelines
of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or
independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable
prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><A NAME="p_008"></A><B>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lucosky Brookman LLP will
pass upon the validity of the issuance of the securities to be offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><A NAME="p_009"></A><B>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of Modular Medical, Inc. as of and for the years ended March 31, 2024 and 2023 incorporated by reference in this Prospectus
and in this Registration Statement to the Annual Report on Form 10-K for the year ended March 31, 2024, have been so incorporated in reliance
on the report of Farber Hass Hurley LLP, an independent registered public accounting firm, as indicated in their report with respect thereto,
and are included herein in reliance upon the authority of said firm as experts in auditing and accounting in giving said report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><A NAME="p_010"></A><B>INCORPORATION OF CERTAIN
INFORMATION BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEC allows us to &ldquo;incorporate&rdquo;
into this prospectus information that we file with the SEC in other documents. This means that we can disclose important information to
you by referring to other documents that contain that information. Any information that we incorporate by reference into this prospectus
is considered part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information contained in this
prospectus and information that we file with the SEC in the future and incorporate by reference in this prospectus automatically modifies
and supersedes previously filed information, including information in previously filed documents or reports that have been incorporated
by reference in this prospectus, to the extent the new information differs from or is inconsistent with the old information. Any statement
so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed
not to constitute a part of this prospectus. For more information, see &ldquo;About this Prospectus.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We incorporate by reference,
as of their respective dates of filing, the documents listed below that we have filed with the SEC and any additional documents that we
may file in the future with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the&nbsp;Exchange Act, including any documents filed
after the date on which the registration statement of which this prospectus is a part is initially filed until the offering of the security
covered by this prospectus has been completed, other than, in each case, documents or information deemed to have been &ldquo;furnished&rdquo;
and not &ldquo;filed&rdquo; in accordance with SEC rules:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px; padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">our Annual Report on&nbsp;</FONT><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024054877/ea0207206-10k_modular.htm">Form 10-K</A></FONT><FONT STYLE="font-size: 10pt">&nbsp;for the fiscal year ended March 31, 2024 filed with the SEC on June 21, 2024;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">the portions of our Definitive Proxy Statement on&nbsp;</FONT><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390025006614/ea0228195-01.htm">Schedule 14A</A></FONT><FONT STYLE="font-size: 10pt">&nbsp;for our 2025 Annual Meeting of Stockholders, filed with the SEC on January 24, 2025, specifically incorporated by reference into our Annual Report on&nbsp;</FONT><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024054877/ea0207206-10k_modular.htm">Form 10-K</A></FONT><FONT STYLE="font-size: 10pt">&nbsp;for the year ended March 31, 2024;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding: 0.25pt 0.5pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">our Quarterly Reports on Form 10-Q for the quarters
    ended June 30, 2024, September 30, 2024 and December 31, 2024, filed with the SEC on&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024068407/ea0210785-10q_modular.htm">August 13, 2024</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024098418/ea0220455-10q_modular.htm">November 14, 2024</A>, as amended on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024103547/ea0222929-10qa1_modular.htm">November 27, 2024</A>, and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390025013462/ea0230149-10q_modular.htm">February 13, 2025</A>, respectively;</FONT></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    Current Reports on Form 8-K filed&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024031921/ea0203660-8k_modular.htm">April 10, 2024</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024072999/ea0212472-8k_modular.htm">August 27, 2024</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024075772/ea0213557-8k_modular.htm">September 5, 2024</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390024102121/ea0222418-8k_modular.htm">November 25, 2024</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000121390025019397/ea0232745-8k_modular.htm">March 3, 2025</A>&nbsp;and&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1074871/000101376225002793/ea0235502-8k_modular.htm">March 26, 2025</A>; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0.25pt 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the&nbsp;Exchange Act&nbsp;prior
    to the termination of this offering, including all such documents we may file with the SEC after the date of the i</FONT><FONT STYLE="font-size: 10pt">nitial
    registration statement and prior to the effectiveness of the registration statement, but excluding any information furnished to,
    rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus
    from the date of the filing of such reports and documents.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We hereby undertake to provide
without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy
of any or all documents that are incorporated by reference into this prospectus, but not delivered with the prospectus, other than exhibits
to such documents unless such exhibits are specifically incorporated by reference into this prospectus. These documents are also available
free of charge through the investors section on our website at www.modular-medical.com as soon as practicable after such materials have
been electronically filed with, or furnished to, the SEC. You may request a copy of these filings, at no cost, by writing or telephoning
us at the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Modular Medical, Inc.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">10740 Thornmint Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attention: Corporate Secretary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(858) 800-3500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should rely only on the
information contained in this prospectus, in any accompanying prospectus supplement, or in any document incorporated by reference herein
or therein. We have not authorized anyone to provide you with any different information. We take no responsibility for, and can provide
no assurance as to the reliability of, any other information that others may provide to you. The information contained in this prospectus,
in any applicable prospectus supplement, and in the documents incorporated by reference herein or therein is accurate only as of the date
such information is presented. Our business, financial condition, results of operations and future prospects may have changed since those
respective dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="p_011"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
and current reports and other information with the SEC. Our filings with the SEC are available from the SEC&rsquo;s website at www.sec.gov,
which contains reports, proxy and information statements, and other information regarding issuers that file electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
and the accompanying prospectus are part of a registration statement that we filed with the SEC. As permitted by SEC rules, this prospectus
supplement and the accompanying prospectus form a part of the registration statement, but do not contain all of the information that is
included in the registration statement. The registration statement contains more information regarding us and our securities, including
certain exhibits. You can obtain a copy of the registration statement from the SEC&rsquo;s website.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><B>Shares of Common Stock
and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>One Warrant to Purchase Share of Common Stock</B></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>Up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Shares of Common Stock Underlying the Warrants</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="image_005.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><B>PRELIMINARY PROSPECTUS SUPPLEMENT</B></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Book-Running Manager</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Newbridge Securities Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "- , # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ I*6OGWXPZUJUG\1K:SL]6O;6WDMH=R03,@Y=@3@=ZTIT_:2L3*7*KG
MT#2U\^>%O%&M^!?B=-H/B74KFYLY7$!DN)2P7/,<HST!R ?K[5]!T5*;@PC+
MF"BBBLR@HHKQ;XT>.+RVO+3PQH=S-'>%EDN7MV*OD\)&".YSD_A5TX.<K(F4
MN57/::*^95N?$GA_XF:1H=YK^HSNL]K]H5KEBI9PK,O7D#.*^FJ=2GR6UO<4
M9<P4445F6%%%% !1110 4444 %%%% !1110 4444 %?-OQN.WXFVQ]+6 _\
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M^3O_ -KH_P"%Y?\ 4N_^3O\ ]KH ]>HKR'_A>7_4N_\ D[_]KH_X7E_U+O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $+ <8# 2(  A$! Q$!_\0
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M5KNH76HW=GJ'@>UUSQJ^@:7X0TNRT]#X<L)+G5+ZZU.:.>, _?:C_)KYN_9
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M@P!?P^]K,?Q\U**8G_']!_U[3?\ HQ* -.BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SX1F[O0/[\7
M_HD&M"J$)(N;[!QF2$_^00#_ "'^<T 6MA]1^O\ A32,'%*68]3^@_PIM !1
M110 444US@?7C^=  6 X_E2A@>E1* 3SZ?X5*!CI_,G^= "U"YR?IQ_.I&;
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M_5CZ]HKY*_X;F_92/7XT^%<'C_F)_I_Q+*4_MR_LH <_&KPL !_U$^V#_P!
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MCMZ%17P;%_P4*^#"^$M9UC5/"WQC\/>/M)\6^"O T7P&U_X=ZAI_QNUOQ/\
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M2I&00PX((P002".0<$ %2G=7LUOOY.Q0ZBBBF 4444 %%%% !1110 5G1?\
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MQDU6!RLG@KP/)OCN8?#DDB^1JVN08^VQB6**5+9F:5/B=\18?BY:W[7E_?\
MAO\ 9VT>[>VOM1MI)M.\3_'/5K1MRZ#X6C/EW4?@07 5-0U546/5XUEV,;4
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M_H P/_A%@_\ YE,C_A&_#V/^0#HP[Y_LJPS_ .D_\O:C_A&_#_\ T ]']?\
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MMRDU92:M!PVO;F;DTL)225^=V;:;EJKVOLHWO9+WKNW79'Y/_MT_!W7?#_\
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MS<E:,$DG:W)S6=[-NZ=FGIULW:W\_/@G_@EC\1X_""6/Q%\!_!;Q)XKBTO\
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MFBBB@ HHHH *:QP,=S_G-1N?F/M_A29.<]Z $HI=JL"&)]>#C]1S2?3F@ R
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M4A>->,D&.54D4ANK;BH R21BO15\56NJQ?:[*[CNXIPL@FB<2!MPYR!DAE.
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M:_F<%/#87!4UA\$HI*2E6K;3J5%=\\Y=+N[>MNZU/J+P%XUOK5[FRUZ]ENK
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M<,'['OP*L/B;JOQ:T;0/$/A[Q5KFMZKXLUBR\-^/?&^@^#-2\<ZU8RZ;J?Q
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M_#/?QZQ_R>/\2,CU\"_#OGZXT?!_3IZ4?\,^?'MCC_AL?XC]AQX$^'@]._\
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MVROB0.!D+X$^'?\ /^R>W.<XSUYXJ%O@!\=P>?VR/B4?<^!?AW[\?\@C\?\
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M!H%F8=6@N;BZU"WTV'XB^+G[<G[87Q?^'&K?&OX<_%OPO\&-.\6_\$[OA?\
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MH4_P1T/PNWBC4I=*T#QA<_"VWURR^#_B=C#KFHW%R/MFJ7%U<1R)U5]X6_;
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MQAB*D$VHN*C%N,8<NME?5R[NVV]MT?0&O_&30+>5K33X[K4Q&[*9+8"WM]P
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M859IHC9G,DJ)'*#$[X>/#7_!2,Y!^)/[)ZY'WO\ A7_Q(8CWV_\ "5*#ZX)
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MH*2 1;9Q_P!<3BNMKD=1(%_=D\ "VR>W^I- %4G/)I&QM.>P)'L:@,WWB&!
M!/!!X S_ "[^W-5VN%P3@\YP<CK^'T_R: '3,0, ]>"/PS^M4G)"G'OP._!)
MIDTX7#'!9CSZ@=L]0 <8'^.*J2W)9< X(/3Y>1ACSQ]!^57"IR-Z7YDUU6VM
MP&/<D?,H ' [%LX/(SZ\D<\YZ5GSWW[ML,P(P>@/&>X]#R,GOV-13N2^W^$!
M>ASD\@\XZCH1T!ZCBN;O[MU1RJMDJ4..G!QR>#R>< 8&/R;J-JW*EY_:];]_
M,#/US5TC#[Y"I!+;CR#@%C@#OS@=LFOG[QCXQ\N%U63AMZMC!/3.?FZ<8STS
MFO0?$!GGCPI&U@PV@DDMS@\\\< \D=/I7S1XZMY(T8MP0S%EW,22%P3VP".H
MY'L<\<U:LX1;NWRK=N]GZ.YI2ASRLWV=K.[\M-;:GS;\6O%EPT5VELS1YR"^
M[D @DD#)(&<9+$@'ITK\\]:^,OC+X?ZI?7>EM!J.FSNKZCHM^[F"YV'!FMIT
M;S;.ZV?(L\>5/'F(W6OM;QS!-=BY15&\[@Q;&",< #&#\HR> #R>M?"GQ&\*
MF<W+-'A@N,C!!!Z?0<Y'?FO#K8^5[64[/1\S3>U]$O7JSV8X2#IJ,XN[2T6G
M+UT:[KO]W?7T#]HWX1_$2XCT3Q!/;^&M9NF(_L/Q=!%_9]S,Q"JEGJ<BG3;H
M2' 593!(V/F4-797?P@URUUW1O'/PRUJV\#^)-*,UQI>IZ=I&DZQH-X+J)K<
MI?:?<1-:W\!A>2 "&6)X4<A)%.*_-[QKX%#M+O@4QX4?<#-\N?F!(Y.<D'(]
ML<UQ_ACXI_&?X/?+\/\ QEJUEI88N_A_4@-8T&8!AE?[.OFE6W5L#>+9XF./
ME"\$=-'$4ZB;OHK)J.KYGYM)/_/J<6)P2@[0E[K6SYFK^>GW7['ZH_$SQI\=
M;O2='T[QCI(&CQS"3Q'XF^$L<G]I7NFF+R;R*X\*ZE+O1Y$.^-=,OY(XG8^6
MJ< ^$_&;XI?LRZ[X/M?@??:7X^7P#+;6&J#5?#SZYX:UJ+Q);([;_&ND-9H=
M2L(;MTD>UOI?L=U-&K*2T2L?._"?_!12[B,-G\5?AG<OO:-;K7? ]XS* B[6
ME.@ZD0X0X4R107KX/W,#BOH_PG\;_P!GGXJ2FWTKQ]X<L;V_41S:1XNAC\/:
MPRS [[.3^U8UBD=6(3,4[*NT 9X<ZR<9+1RY>ST=[6V3W[,Y'2<++V5VK-SU
M=UV;U72]NR.!_9S^$6O^!-2?5[/XV^*O&'PTN-.']C>!M1N9)]%L[ZZ5"+]S
MJ7FW&GW5E$/+2TT^9(9)"YD#QX%?85_XDT72+5Y]1U33;&&)"TDMU<11A54?
M,?OY/T"]>@ZY\ZC_ &4/!.NO)J-K>ZWY-Q"PLDT7Q1J,NFVX!WA[.VM+Y[4+
M(S$":-6VY90=H&.R\)?LA> =+FCO+^PU7Q'*A,Z+KFIZKJ%O&2N'66":7RG=
M(P6$3@[?GRKL17?0QTZ5.-*G0=HK23GJV]VU=-;Z=+_,XZF&A5FY5)^])M\G
ML[+3;5)+ULKG$:5XDU3XMW]SX>^%1FGM8Y6M-;\;O _]EZ>"/WD.F%B!=76T
MD$HWF!EQM1=U?67PY^&^F>"],MK>U5FN791>:O<QD7.J3?\ +PT[ ,SP3,V^
M6!6$7S=3M IFI7WPR^#>@";Q+XB\&?#GP_8PR2I;7NHV&C(KKEMD>F(ZW+RS
M;PQ$5O)<$D,/OG'QA\1?^"E_PST-O[&^"W@W7?BWK,<C+:ZM=QW'AWP=!*&7
M9))>W:'4M2",&11:6D:2@F3SOF.%*NJDF\1*[YKQBG?E3M9+OJM]?4%AG"T:
M4%;?6+M=IZWZ/9_UI^I%F8K!'FO)HK=;96,\]Q(EM:Z=;?*T\ZWT[I:PPNBL
MSEI4*HN_<K<#Y0^)7[8FF6]W-X(^!T$'CWQ6))[.?Q0D3?\ "'Z%*W[MGM'5
MMWB*^C)RD4.RPAD7<9Y4Q%7YWV&J?M*?M6ZA!-\2==N=+\+27!E@\#^%DET?
MPQ;(T@V)=VZ.9]49(\(9KZ>;S !F-<8K]0/V??V9M+\,-8^;IJ!X]AW-"H*D
M$;0  !R![C]<%/$2<E"#M'SNW9?E>W6V^A?L%&?-47-+E:5KI)7>^MGKOK>U
MUV*O[/\ \'/$&L^(/^$U\?7-_P"(/$^J,);O5-3Q+.9"H/DP!AY=O:Q E8K:
M$+%$@547Y17ZG>%O!MM:P0K'$@\L(-HC"G@#T X!X(').3]+'@SP;8Z?$@BM
MTC95( "*J@8&?E(P<^HXZX'%>QV%@D"!47:<#<& SCT!Y^8]>Q((-=U%KEG)
M[W5WIU5[+_+K?J6HJ*T5D-TRP\J,+R"&4X"8Z8QSZX(SQQG@')KJ8(UR'P,<
M#'?*X&<]SQW]>O'-.-%C4  CJ!G/KTYX_EUK0@^ZO^]G\,CG]1^=;2C[K;2V
M5GUWUMZZ6&:L"XRV>HQC ['.<]?_ -9JU'P>/3^HJO#]P?4U:3H?K_05*TJ/
MT?Y?U<"S$[9VY)7!XZ^G0>WM6M98^VJ#C)M9#@]<F2//'YUD0_?'T-:=E_R$
M$R<_Z+)_Z''[#GZY[<UC6E=\J>BW5]=[Z^5_\@.@HH'  ]**P *0@=<#\A^=
M+119=E]R_P @/BCXV_L(_!GX]_&63XR>-9_%D-]KWP*UW]G3XC^&?#^OWGA[
M1OB5\-;WQ99>/O"L.LZCHLEAXGT;Q!\._&=M?:WX0\1^%]=T;4;4:]K6GW4M
MW97BQ0\SX&_X)M_LT?#'QG^S;KOPX\.WW@KP;^RS?_%?Q;\-?A=I5U]J\+7W
MQ;^,6F#0O%GQG\<:KK*:GXN\9_$1= NM?TW3]8UOQ!.89?$VK:C.EQ??8Y;7
M[]HH ^6O$G[%'[+'B[XL7?QS\2?!;PCJ_P 6K_XA_";XKWGCBZ34#K$_Q$^!
MGA_6O"GPE\5NR7R6W]I^!O#WB+6M*T9A;B%;;4)Q<PSOL=>!L/\ @FM^POIG
MAC6?!EC^S9\/(/"_B#X/>/O@#K&B_9=1ELK_ .#WQ0\>S_%'QYX$FCFU"0_V
M1XB^(5S-XMNF0K>1:P4N+2YMQ'&B?<=% 'YNV/\ P2-_X)[:;X5T[P/:?L[Z
M.O@^T\?:;\3]4\-W'BOQ[?Z3XT\=Z/8^'M/TOQ!\1+34/%%U'X_N;"#PIX<:
MUA\6_P!K6D$^D6<\<"R(S-H^-O\ @D[_ ,$\_B':^$+'Q5^S!X$OK+P1XA\;
M>(]'L[:X\1:5;7<WQ(\8_P#"P?'FC>)8=+UJSC\7^$O%7C=8O%&K^#?%*ZOX
M7N-7@AN1I2;2K?HC10!\J:+^Q!^RAX<\:Z'\1-"^!_@S2O&?AKXR^._V@] U
MVRM[V"YTGXR_$SPA:> O'7CVRC2\^RP:OXB\'6%EX?O$2W%BFGVT4=M:0LNZ
MO.O'?_!,S]B'XH^+/C!XY^)7P)T/Q_XM^.6BCPYX[U[Q?K7BK7M030UU^P\6
MIIG@^XU#7)G^'UK%XKTK3?$T">"#H!M]=L+74+=HIXE-?>%% 'R'X>_83_9?
M\,>,/@!\0]*^'<Y^('[,?AOQ;X.^#OCG4/%_C/5O%F@^%?'4\UWXJ\/:OKVI
MZ_=ZAXOTC5KZ8ZC)8^+9]:@M]0C@O+1+>:WA=/KP?Y]O;CTHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N&UV39J$R _?CA9AUZ1X!QGL."./7K7
M<UAW]A:7%PTDT(=RJ*6WR*<!2 /E=1P"?S- '",V3R<>@R 0".^#W'UJI)(Z
MEQN)4Y^4D%<8' P,\Y)Z]?IBNX.D:<00;<$$8/[V;..G7S,]/>FMHFEM@&U!
M  /^NN.I SSYN: //FE'/\)R#@'/'XD9Z'C@'ZU4DN5VD@%CD@CCL#Z'VKTA
MM TAN#:#U_U]R/Y3"JTGAW1LM_H?;_GXNO3_ *[T >4S70:-BD3+Z$%N&')S
MZ]\^OMS6%?RX4X&%*DL"<\\'.2,C.1G\^F*]H_X1O1?^?+_R8N__ (_5:Y\(
M^'IO]9IP;Y,?\?-XO'R_W;@>I]ZF3:5UW"U]&?+.L7.TN(]K!5?:<_*I )/'
M\1R0?7/'-?/GC!)KIIOE/R@YD50WWL@C'&,\Y!Y SSTK] +CX?\ A&9YDDT@
M,H)4#[=J0&/E&/EO!_\ 6[5BW_PH^'\@^?P\C9!S_P 3'5P#UZ@7X!Z=37'5
MIRJ-ZI*72SMTWLU_6YV4Y0I\C4&VU%W;ZWOLM.GW'Y"^)M%)+EH\KSN!!YQD
M$'@?=],GD'&#7S=XI\+QW<DJB ;I.P7).<^N #[$X!XK]V-2^!WPLO(RMSX5
MCD#E@P_M;7DR P&/DU1<<'MBN'N/V:O@E*\C2>!XF;+<_P!N^*!W]%UL#L/K
M7CU\))U7%2BDFK+WNL5_D>Q#%P;O*$MEHFNEUUMV/YW?$OPPBF28M;#YLX&W
M)7"G)Z>G3 ]O>OGK7?A=$I=3 2 3\I3@ G&!GL<XX_H2/ZDKC]E[X$S+B3P%
M"^>#G7_%0R"",$C71VX_/U-<G?\ ['O[.%R09_AI:R$,<$^(O& Z=/N^(1Z5
MFL+5C>U2*M*]ES)-I7N^_P"A<L52DOX<KZ:M0=]+-.]]+=M;JY_)EXC^%$;"
M5X[7IDA!%CJ!G@8R"?;\>F/#M4^%>9G<V.]D/R$Q!G7!QE21G)7/(Y[C!&:_
ML=NOV*OV8IT/F_"VT?B0?\C-XV''/'R^)1_GZ5S<_P"PA^R?*6>3X163-M7G
M_A*O'8ZE<\#Q2!SD]N];VQ-XKVD-4NDOZ>WWF?M*+7+RU$FM$G&WP^OWG\C>
MB:'X]\/A/^$9\3>+-$5 %C73=<U2TCC57RJI''<B-4&3\@4*"3QVKM<_M#:I
M%):GXH?$I[:4?/!_PE&K>3(O1&^2<'(&0-K# /?!K^J^+]@[]DY&7;\(K(8)
M./\ A*O'A&>N<'Q2>_\ ATKK]+_8H_9@MMGD_"JQ7 !&?$?C.3H&Q_K/$;]/
M_KUVTXU9_%.+:[)K;\_(Y&J#3DXSNF[.\=D]MMOZW/Y(=#_9L\9>)-4CU'7&
MU77[IY4D-UJ]W?:I=;U &[SKZ69E)4X!4@C/7!R/T%^#/[)@C>UDO=*V[C&V
M)K<$*00&SD< <D>YSGDBOZ+=%_94_9_TL(+#X<6%N%5,;=7\2/C..<R:TYSP
M.3S7H^D_ CX363Q-:^#[:(H/EQJ6ML!A%;[KZFR_>)."*U="6CYEWV;V?GZ'
M/4J1ORI/E45T2=KZ+MZO?5GY\_"KX(Z5X>L8!%8Q A$+,L2KTP K*5;A>@*X
M)]>17UWX?\+Q6J(T<:HR["0(P'."  21[=AZ]S7TS8_#KP9:J@M]#BC"D  7
M>H, "!D8:[8?_7YZUO1>#_#D9.S3$'(/_'Q>'JP];@^O3H.U=M.FH)=9-:LX
MIU/:6=K:6/*-)MR@7<N"JDG.03C&0 /8\#IP>G%=E;#?G)_CVJ3P,8![8SC'
M).<8Y(KM(O#>B1.HCL54#IB>Y/4(3UF.>IZ^M:<>AZ7DG[(N?^NL_?/_ $UK
MHA.,;W4G=IZ-6TOT9!Q<<*\-G)7D^A.>!D>W;//M5^*$[0V5Y.>23@<$XXQ@
MC&>W2NICTJP!(%O@8S_K9O;_ *:4]-+L2N?(YR>?,F'1B!TDK7VL=VGS+2ZL
MUUZ-^NNX'/KM4!5P!DX QW_SQ4R<'OD]!V/?_/U]ZW_[.L_^>(_[[D_^+J46
M5L,8BQ\I_CD[;O\ :J55CS7:=WM:UM=.NH&3"H"EL$$D@Y[X]!],?_6Z5>L>
M=07KQ:OG@_WHZT6M8,G]WW/\3^O^]4D=O#',CH@#>2RYRQX+(2,$D<GVK%S4
MVVE;5WOU?]("W1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A ,P# 2(  A$! Q$!_\0
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M!E(*D9!'<5X!\<_!GV2]C\36<>(9R$N@H^Z_9J[;X.>,O^$B\-_V;=R9U"P
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MM:&<90<]'J6**2EK$W"BBB@ HHHH **** "BBB@ HHHH **** $->1>. /\
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'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &> EX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **,T9![T %%%% !1110 4444 %%%% !1151M2LU8J;B,$<$9J
M92C'=C2;V+=%4_[4LO\ GYC_ #H_M2R_Y^8_SJ/:T^Z*Y)=BY15/^U++_GYC
M_.C^U++_ )^8_P Z/:P[H.278N453_M2R_Y^8_SH_M2R_P"?F/\ .CVL.Z#D
MEV+E%4_[4LO^?F/\Z/[4LO\ GYC_ #H]K#N@Y)=BY15/^U++_GYC_.C^U++_
M )^8_P Z/:P[H.278N453_M2R_Y^8_SH_M2R_P"?F/\ .CVL.Z#DEV+E%4_[
M4LO^?F/\Z4:G9$@"YCR?>G[6'="Y)=BW5!]3/GR116LTOEG!91QFKX.:QK>2
M[2]O1! DB^9U9\<UH2:5M</.&+P218_OCK4P(/0YK*O;NY46\+V[[Y6.Y8CG
M@>]-M1-'>(L-K/%"P._S#Q0!KY&<9&::TJ+*L98!V&0,UD3FT#LS-/),/^6B
M#@&E-K#<W]E<2AC(8R<YQ0!LT5!&3]LG&> %XK*OVF:UNUCF9&\U0&'89H V
M\CUH!!Z'-9%X?LLD-M#%-()B6<H<G HMA.ESL@MIH8F0[C(> >U &OD9QD9I
M:QDAB5E+M-!<Y^^QX)K9[4 %%5WO;:-RCS(&'4$TG]H6G_/=/SK-U(+J5R2[
M%FBJW]H6G_/=/SH_M"T_Y[I^='M8=PY)=BS15;^T+3_GNGYT?VA:?\]T_.CV
ML.X<DNQ9HJM_:%I_SW3\Z/[0M/\ GNGYT>UAW#DEV+-%5O[0M/\ GNGYT?VA
M:?\ /=/SH]K#N')+L6:*K?VA:?\ /=/SH_M"T_Y[I^='M8=PY)=BS15;^T+3
M_GNGYT?VA:?\]T_.CVL.X<DNQ9HJM_:%I_SW3\Z/[0M/^>Z?G1[6'<.278LT
M56_M"T_Y[I^=217,,Y(BD5\=<&FJD6[)@XR6Z):***LD**** "BBB@ HHHH
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M[<!SE^IKE?$ND2$KJ$*,Y<[9%')]J[HH,8J%(]HK.4KA4H1J0Y&<'8>$[Z[
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MAMU*Q[BV"<\FK3&H'-)ML:21%(:P=9L)KIA)!)&#C#)(N5/O6T3ND$: O(>
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M,>E)L4@#:,#H,4 550O\[.^0HP.E110CSI!O<,[@D9[5HXI-HSG SZT 496
M63+L)1D!?:H%,@X3 4A=Q/':M7:I;=@9]:-HQC Q0 R!66%0QR?KFI* ,# H
MH **** *UW#O4..J]?I7G5UI^H6WBJ:>:;=I\J;4BQG=GK7IW:LJZMU2;)4$
M?PDCI6-2-]17MJ>7W&F)I-P\4*;89#O7%"$5V.M:4MS 2HQW!'\)KCGC>"0Q
MRC:P_6N.:9Z-"HI1)0:4&H@U+NK(Z27-)FH]U)NJ0'DTTM3<\$] .YZ"JR7M
MM,&,-PD@4[6*G.#Z4[!<G+5&S!068A1ZDT^VL]2U*3R[&S<\X\R0845T^F_#
MKS&675KAI3U\L<*/PJXTY2,9UXQ.-CGDNI/+L;=[A^F0,*/QKH-,\!ZAJ6)-
M3F*1GGRTX'_UZ]%LM(L=/C5+>!%QTXJ]75##I;G).O*6QCZ5X9TW28PL$"9'
M?%:X  P!BEHKI44MCG;N%%%%4 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 1SP1W,#PRC*.,$5YIKOAVYT5FE0&6V+?*PZCZUZ?3
M9(TE0I(H93U!&12:N-.QXE>JUSILZ0,1(5(&.N:SO#-Q<R6\UO<A\Q' +]?I
M7K]]X/TVZ#&)3;R,VXLG^%8WBO0_LRP7%I;Y14VRE!Z=S1>T7&Q+C>HIW.82
M5E[Y%7;>\6, 9.2>2>0!6:CJX..".U2*:SN;VN;1U&.2$Q!%!#9W^HJH;H1O
M\O)JER&IO\5)L5C2:5I""QS1FHXP7VA023V%=#IOAJ>YVR71,4?]WN:%=AHC
M)MK2>\D\N",NQ].@KK=*\/16BK)<XDE].PK5MK2"RBV0HJ*.IJK>:[I5AG[3
M?P1D=BV:T4;$-W-$# P.E%<VWCSPXIQ_:*'Z U/;>,= NG"1ZE#N/0,<51)N
MT4V.1)4#QNKJ>A4Y!IU !1110 4444 13[B@"MM).,U5:2Y,IV*/D. ">M7R
M >M-,:%PQ4;AWH I"1Q)$WF_?)W)Z47%RPF@5'&&'/>K#6L9F60 *P.3@=:<
M((5.1&H/KB@"K(TZ!55BV_)+$XQ[4R1I7AD69]A5>,'K5]D5EVLH(]*1H8G
M#1J<=,B@!+?_ (]X_P#=%24  # Z44 %%%% "T4E+F@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HII=0<%@".>:
MZD@!@2>: '44A95ZL!]32T %%(&4L5!Y'44M !1110 4444 %%(6 4L3QZT
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M_O#GU%$<*1_=7%5Y)IHHQ(")-W&T=JC\ZZ,L<9^0,W+,!DB@"5;,&<NX&!T
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MK" -SG J-Y\?+$/QHL%R,Q1Q#+X^E5Y'+<*NU:D*ECDY)I-M%@N4VA![5&T
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M_I0@)****H HHHH **** .=\:VLESX=E,8),;!R!Z"O.[+!C#YZU[*ZJZ%6
M*D8(/>N$UKP=/!(T^EC?$QW-#GD?2F-& $STJP4MFC)V2)(/0Y!JB[3VB,DE
MO+')GAF4X'M4R:DL4D;!1)CE@PQS3 #O0\@TUI7(P#Q4EQ>?:)&D88W<X JF
MUP > 2?I0!##I-H@D81A03N(!_E6_P"%O#EC?WK-+ 7AC'.3P35?3="U'5Y%
M*1F.$GF1Q@ >U>CZ7ID&E6@@A'NS'JQI\[MN(EM+&UL8]EK;QQ+Z(N*L445
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M%:&A>&M9\6W&+2(QVH/SW#C"*/;UH'8I6]UC4;2"U0L[3)]T9)YKZOM@1:Q
MC!V#/Y5P/A7P3I'AA4>&,7-Z<;KF49/X#M7H0Z"J2L)L6BBBF(**** "BBB@
M HHHH CE@BF&)8D<?[0S5?\ LJP+;OL<.?\ <%7** *HTVR'_+K%_P!\BE_L
M^S_Y]8?^^!5FB@!%4*H50 !T I:** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BFAU+LH/S+U%.H C>%)&#-GCMGBI*0$$D=Q2T %%%% !1136=5*AC@L<#
MWH =112 Y&10 M%%)D9QWH 6BBB@ HI,C..]+0 4444 %%%% !1110 4444
M8OBN$3^&+Z)AD-'_ %KYYU;1KRSN%VY>W?H_I[&OI#6XS+HUR@&25KSM]-,L
M+1R1@HPP0:E@>:6NE1K@OEF]Z;=;K>22!_ER/D.*ZB]TI]+G"GYHG^Z_I[&J
MUS#!/"4F0,OZB@#CC!('_>8 7GZUMI<HZQQY*LP[>E,:SAB;$2L?=CG%--F&
M8.Q(8="*=@N:S)9WT(@N4"MC"R#^M9]KX2D6\$<<IB3.XR9R,>U"&59%CQN#
M' ]JZ6#]S&L8).VDW;1C2['3:/:6-C;B*T0!L?,Y^\QJ>]U.WL4.\[I.R+UK
MG/MLD2[8R=Q[^E,_LR]N(6N$&\]2,Y-4F0T/GO+S5I=F=J$\*#@"J=]87MBP
MWQD ]&'2H[6:6"<&0%2#T/:NVTR^MM2MOLMV P;@$]J%KH#T.?T356M749QC
MKFH?&_@T:[;G7M"4"]C&;BW7I(/4>]7M8\.S:?(9$YB/*O7&:EXSO;*\73M.
M<[EYD<'I[4O)CWU1B6MU-;86XC9#TY%.UZXN;NUM[: MY4AS(RGMZ5WNFV<-
MQ;"YGA5Y)AEMPXJ2+P[I;:A'"D3F1OF\H'Y0/4TE$J]RGX%T[^S=*DN[@^6C
M\+GT]:U+OQ=;VDP$<7FH.H!Y-=3;V4%NBHZ*PQC!' 'L*\Q\:Z<--U@_91LM
MIANSZ&L\0YTXWB>IE-'#XBJX5?D=';65MJ.MP:Q-JDT\#\VL .T1GN#ZU)K*
M%;LMN+*_/T/I7$Z+J8BLV@1B?+E#*<UW]O9W&K[))4,-N!P2.370L1*M!.1Q
MXO#JA7E".QYEXSC\IH+@.!G*,N>37,:7]KD;[':QO--(>$09->\:OX+T+6[6
M."[MV#1_<E1L,*L:!X8TGPU"4TZWQ(?O3/RY_'M4<KN8<RL<?X8^%X!2]\0M
MN;[RVBG_ -"->F01Q6\*P01)%"HPJ(, 4T$DYIZU:21#=R>,_.OU%="/NCZ5
MSL?WU^HKHA]T?2DP0M%%%(84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %1S%EA8KUJ2B@"CO4'"2,8R/F/7%*3&" 9F\H].>_P!:
MMA% ("@ ]>*/+3;MV+M],4 4XV"7$A+$KE?F/TIGF;]Y,GRASP3C(]JT"JD8
M*C'IBD\M",;%QZ8H HAR96#,PAPO)[4^-?,D;]XY1<[>:N%5(((!!]J  !@
M 4 4F8"52[DD@84'!%+>R;.5#%@.,'%7-BE@Q49'?%!56()4$CU% %7:SAI=
MS;@H('8&H 5::W)=C+O^8>E:6*;L7=NVC/KB@"L[NLYA!/S?,#Z#O59&GD !
M=5'\)8D5J8&<XYI"BG&5''M0!GO)*A.YCF'EL=#GI2J'>Y2-G?;M!(J_@'/
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M2:144>M5KNYN!;.;?AATR*Y&Z>2XD+SR%V]ZTIX:3W)G72V.UTFZ^UWY9%S
MJ;@_J:W@X R37%^%+[:TEHQ& ,J?6NEN)BL(P>M85H\LK&]*7-&Y:,Y=]JG
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M0@^\H]*1(DD8-Y9V!LKGM0!<[4444 %%%% !1110 4444 %%%% '->/XO/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
L0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "- , # 2(  A$! Q$!_\0
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MX_ECKU_GQQQQ5L'/^?K[#TK_ #Y/V"OV\?VNO^"5?_!7_P 8?L7?\% /C_\
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ME5HQ;=Y^ZW*,;RDDTXWLU'EQD?[+S*GFJ^"4:<9<JTU45?1J*T>[6Z6JT/\
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M<K7[.$IREJXIR?O:II6^9?\ PK9J]GE>3MI]5.HTG:UM;/1K71JRUL_X*?\
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M^.K96V/ZW+%%%% KKNOO7^84444!==U]Z_S"BBB@84444 %%%% !2-T/T/\
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MX,6+29->\,ZP=*\4:V_Q(\$)/HEP/^%@^#O#N@ZW_P (G'$8YG>1"MVFXJ/
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MBU!X#T?X=?$_XQ_"/XL?M,_"/PUX'^-'A_P/\0O"WA3PQX?\1?%OX8^(M?\
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A8?\ HQ _^)0C_P"AVH_XBK#_ -&('_Q*$?\ T.U '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
